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ABSTRACT 
SARAH R. UZENOFF: Evaluation of a Multi-element Treatment Center for Early Psychosis: 
Predictors of Functional Outcome at 1 Year 
(Under the direction of David Penn, PhD) 
 
 Background:   A growing international body of research has demonstrated the 
potential for comprehensive, phase-specific care to improve clinical and functional outcomes 
in early psychosis. However there have been no evaluations of such treatment models in the 
United States (US).  This study is a naturalistic, prospective one-year follow-up of an early 
psychosis cohort treated in one of the first US-based multi-element treatment centers. 
Method:  Participants were 163 individuals treated at the Outreach and Support Intervention 
Services (OASIS) clinic, a multi-element treatment center for early psychosis. Data were 
collected as part of routine care at six-month intervals. Primary outcomes included role 
functioning, involvement in work or school, and subjective experiences of recovery. In 
addition, a novel definition of functional remission was proposed. Predictors of functional 
outcomes were examined using generalized estimating equations.  Results:  After one year of 
treatment, individuals experienced significant improvements in positive and negative 
symptoms, role functioning, and clinician- and patient-rated global functioning. Individuals 
were significantly more likely to achieve symptom remission, functional remission, and to be 
in school at one year than at baseline. There were also trend-level reductions in substance 
abuse. Symptom remission and age of referral emerged as significant predictors of role 
functioning across the first year of treatment.  Individuals with active substance abuse over 
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the course of treatment had poorer role functioning by one year than did individuals not 
abusing substances. Discussion:  This study provides preliminary support for the efficacy of 
comprehensive early intervention services in the US. Limitations and implications for future 
research are discussed.
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INTRODUCTION 
Over the past two decades, a paradigm shift in the treatment of psychotic disorders has 
pointed research and treatment development efforts towards the early illness course.  As a 
standard of care, early intervention seeks to minimize the treatment delays and stigma which 
have long prevented individuals from receiving optimal treatment early in the course of their 
illnesses, and to minimize the mortality and morbidity associated with illnesses such as 
schizophrenia (Lieberman & Fenton, 2000; Malla & Norman, 2002; McGlashan, 1998; 
McGlashan & Johannessen, 1996; McGorry, 1992; Stephenson, 2000). The early phase of 
psychotic illnesses (including the pre-psychotic period and extending through the first 3-5 years 
following treatment initiation) has been recognized as a critical period for treatment (Birchwood, 
Todd, & Jackson, 1998). This is the period during which much of the negative clinical 
progression in schizophrenia has been hypothesized to occur (Lieberman et al.1998), and early 
outcomes during this period are one of the strongest predictors of long-term symptom and 
functional outcomes (Harrison et al., 2001). Given evidence that biological, psychological, and 
psychosocial influences may demonstrate maximum plasticity during this period, interventions 
targeted at the first episode of psychosis and the period immediately thereafter may have a 
disproportionate effect relative to later interventions (Birchwood et al., 1998; McGorry et al., 
2007).  
Rationale and Aims for Early Intervention 
The rationale for early intervention in psychosis has been further bolstered by findings 
that refute the notion of a progressively deteriorating illness course. Instead, prospective
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 longitudinal studies following individuals who have recently experienced a first episode of 
psychosis have presented findings consistent with the an early plateau in the illness course 
that may be followed either by stability or by continued recovery (Bertelsen et al., 2009; 
Crumlish et al., 2009). In light of these findings, a recovery movement emphasizing 
optimism, access to opportunity, and pursuit of individual goals and meaningful community 
participation has gained momentum (Lieberman et al., 2008). International healthcare entities 
including the World Health Organization and the International Early Psychosis Association 
(IEPA) aim to raise wider societal awareness about the importance of early intervention 
while generating optimism and expectations of positive outcomes and recovery (Bertolote & 
McGorry, 2005).  
Nonetheless, long-term follow-up studies suggest that psychotic disorders continue to 
be associated with significant impairment and morbidity, including high rates of suicide 
(Bromet, Naz, Fochtmann, Carlson, & Tannenberg-Karant, 2005), frequent symptomatic 
relapses (Robinson, Woerner, Delman, & Kane, 2005), and difficulty returning to normative 
social roles (Robinson, Woerner, McMeniman, Mendelowitz, & Bilder, 2004). Accordingly, 
there is a pressing need for the development of treatments for the early illness course that can 
improve outcomes in these varying domains. Thus, early intervention for psychotic disorders 
has the following primary goals: a) reducing duration of untreated psychosis, b) accelerating 
remission, and  preventing relapse and treatment resistance, and c) maximizing social and 
functional recovery (Birchwood et al., 1998; Spencer, Birchwood, & McGovern, 2001).  
These goals are described further below. 
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Reducing duration of untreated psychosis. 
A converging body of literature suggests that the sooner antipsychotic treatment is initiated 
after the emergence of active psychosis, the better the clinical outcome. Duration of untreated 
psychosis (DUP) (i.e. length of time between the onset of an individual‟s initial psychotic 
episode and when that individual receives treatment) has been found to be predictive of 
clinical status upon presentation (Melle et al., 2004), as well as short-term symptom levels  
(Larsen, Moe, Vibe-Hansen, & Johannessen, 2000; Malla et al., 2002a) and social 
functioning (Addington, van Mastrigt, & Addington, 2004a; Barnes et al., 2008). Recent 
prospective naturalistic studies of FEP cohorts have also reported associations between DUP 
and long-term outcomes including symptom burden (White et al., 2009) and social 
functioning (Crumlish et al., 2009). 
There are consistent associations reported between DUP and a variety of other 
indicators of prognosis, including age of onset, sex, premorbid functioning, socioeconomic 
status, and mode of illness onset (Norman & Malla, 2001; Perkins, Gu, Boteva, & 
Lieberman, 2005). Some have suggested that long DUP and delayed treatment may be a 
consequence of some other indicators of poor prognosis, in that an insidious illness onset and 
premorbid dysfunction would likely contribute to delayed help-seeking and delayed initiation 
of treatment (Barnes et al., 2000; Verdoux et al., 2001). However, suggestions that the 
relationship between DUP and outcome is confounded by these other factors are consistently 
not borne out in empirical studies (Singh, 2007). A systematic review (Marshall et al., 2005) 
and a comprehensive meta-analysis (Perkins et al., 2005) have concluded that prolonged 
DUP is modestly but consistently associated with poorer short-term outcomes in an array of 
domains, including symptom levels, overall functioning, quality of life, and likelihood of 
 4 
symptom remission, and that these associations persist after controlling for the effects of 
other confounding variables, particularly premorbid adjustment. These findings therefore 
highlight reducing treatment delays as a malleable prognostic factor and a primary target for 
intervention studies aimed at improving outcomes.  
Accelerating remission and preventing relapse and treatment resistance. 
 Antipsychotic medications comprise the frontline treatment for most psychotic 
disorders, for their efficacy in treating symptoms and preventing relapse (Fenton, Blyler, & 
Heinssen, 1997; Malla et al., 2006) as well as their potential to attenuate some of the 
biological correlates of disease progression (Lieberman et al., 2005b). Medication response 
following an initial psychotic episode is typically quite good, with a majority of patients (i.e. 
between 50-75%) experiencing significant improvement within 3 months of initiation of 
antipsychotic medication (Lieberman et al., 2003b; Schooler et al., 2005) and maximum 
symptomatic improvement occurring within the first 6 months of treatment (Szymanski, 
Cannon, Gallacher, Erwin, & Gur, 1996). Although estimates of the proportion of first-
episode patients responding to acute antipsychotic treatment vary (based on the length of the 
medication trials, the definition of „response‟ used, and the type of antipsychotic drug), most 
individuals will experience remission of psychotic symptoms in response to an adequate trial 
of antipsychotic medication within the first year of treatment  (Bradford, Perkins, & 
Lieberman, 2003; Lieberman et al., 2003a; Robinson et al.1999). Negative and cognitive 
symptoms tend to show less improvement following initiation of treatment with 
antipsychotic medications than do positive symptoms, which may represent a different time 
course for responsiveness, and/or more refractory properties of these symptoms (Bradford et 
al., 2003). International clinical practice guidelines for early psychosis include a 
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recommendation of pharmacotherapy for at least one to two years following symptom 
remission, with longer maintenance treatment for individuals who are slow to respond or who 
have frequent relapses (IEPAWG, 2005).  
Symptom remission: clinical phenomenology and correlates. 
Effective management and reduction of symptoms following an initial psychotic 
episode is a central goal of early intervention. Symptom remission is a generally accepted 
marker of symptomatic improvement, and one which holds advantages over other suggested 
heuristics (such as a 20% reduction in symptoms) that disregard baseline symptom levels and 
may have limited generalizability (Mortimer, 2007). Similar to the concept of remission in 
other psychiatric illnesses like anxiety and depression, symptomatic remission in 
schizophrenia is defined not by an absence of symptoms, but by minimal symptoms that are 
associated with no more than a mild level of disability. In recent years, a consensus definition 
for symptom remission across the illness course has been established by the Remission in 
Schizophrenia Working Group (Andreasen et al., 2005). This definition pertains specifically 
to core symptom domains (including psychoticism/reality distortion, disorganization, and 
negative symptoms) that were chosen to map onto the three dimensions of psychopathology 
identified by factor analyses and the five criteria for schizophrenia specified in DSM-IV. The 
resulting remission criteria have been operationalized onto select items from several of the 
most common measures of psychopathology, including the Positive and Negative Syndrome 
Scale for schizophrenia (PANSS)(Kay, Fiszbein, & Opler, 1987) and the Brief Psychiatric 
Rating Scale (BPRS) (Overall & Gorham, 1962). The definition includes both a severity 
component (i.e. mild or less) on each of the selected items as well as a time component (i.e. 
that symptom levels should endure for at least 6 months). 
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This definition of remission has been shown to be a sensitive and specific indicator of 
clinical status (Opler, Yang, Caleo, & Alberti, 2007). It has been validated by findings that it 
correlates significantly with established measures of symptom severity, functioning and 
quality of life, and appears achievable for a significant proportion of patients across the 
course of schizophrenia, including those with recent-onset psychosis (Lasser et al., 2007; van 
Os et al., 2006a; van Os et al., 2006b). Additionally,  the remission concept has been 
demonstrated sufficient plasticity as an outcome measure by findings that clinically stable 
patients not yet at the remission criteria move to better clinical outcomes when exposed to 
adequate treatment (Lasser, Bossie, Gharabawi, & Kane, 2005). 
Remission rates in first-episode psychosis (FEP) according to these criteria have been 
reported between 24-48% within the first 5 five years of treatment (Addington & Addington, 
2008b; Bertelsen et al., 2009; Emsley, Rabinowitz, & Medori, 2007; Wunderink, Nienhuis, 
Sytema, & Wiersma, 2007), with higher rates of remission reported (36%-77%) when only 
the severity criterion is required (Addington & Addington, 2008b; Boden, Sundstrom, 
Lindstrom, & Lindstrom, 2009; Emsley et al., 2007; Menezes et al., 2009; Petersen et al., 
2008).  Indeed, in a secondary analysis of six studies including participants with varying 
illness chronicity, Dunayevich and colleagues (2006)  reported that only about 1/3 to less 
than 1/2 of the patients meeting the severity threshold for remission maintained this level of 
improvement at the one-year time point, leading the authors to conclude that  meeting the 
severity threshold alone holds limited utility in predicting sustained improvement at later 
time points. However, Cassidy and colleagues (2009) found that the predictive validity of the 
remission criteria did not decrease when a 3-month time criterion was used rather a 6-month 
criterion.  
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The association between symptomatic remission and a broad array of outcomes 
highlights early and sustained symptomatic remission as a primary treatment goal in early 
intervention. First, early illness course, including early symptom remission, has been shown 
to predict longer-term illness course. This has been demonstrated in a 24-month follow-up 
study of 2,690 individuals with varying duration of illness (Lambert et al., 2006), and in a 5-
year follow-up of a first-episode cohort in which failure to achieve symptom remission after 
two years of treatment was found to predict a continuous course of illness at five-years 
(Bertelsen et al., 2009). Additionally, persistent symptoms are among the highest risk factors 
for prematurely disengaging from treatment. This has been demonstrated both in community 
treatment (Schimmelmann, Conus, Schacht, McGorry, & Lambert, 2006) as well as in 
clinical drug trials for FEP (i.e. comprising non-epidemiological samples) (Perkins et al., 
2008). Therefore symptomatic remission early in the illness course may have significant 
impact on future illness course and treatment engagement.   
Symptom remission has also been found to be associated with satisfaction with life 
(Boden et al., 2009), well-being (Lambert et al., 2006), and self-reported quality of life 
(Emsley et al., 2007; van Os et al., 1999; but not Wunderink et al., 2007). Van Os and 
colleagues (2006b) found that changes in symptomatic remission status were associated with 
large and clinically relevant changes in clinician-reported and, to a lesser extent, patient-
reported functional outcomes in schizophrenia. Boden and colleagues (2009) found that 
symptom remission had adequate discriminatory capacity for determining good functioning 
(as defined by objective measures) from poor functioning in a FEP sample.  Furthermore, 
individuals with remitted symptoms may require less support in activities of daily living and 
require less health care resources (Helldin, Kane, Karilampi, Norlander, & Archer, 2007). 
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These findings (discussed further in following sections) support the assertion that symptom 
remission may in fact be a prerequisite for social and functional gains (Andreasen et al., 
2005; Robinson et al., 2004; van Os et al., 2006a). 
Relapse: clinical phenomenology and correlates. 
Unfortunately, despite the fact that many will achieve symptomatic remission 
following an initial psychotic episode, relapses are frequent. Relapse rates of 21- 33% are 
reported within one year of initial hospitalization, with the rates increasing up to 40% by 
three years (Chen et al., 2005; Ucok, Polat, Cakir, & Genc, 2006) and to over 90% within 5 
years of initial treatment response (Perkins et al., 2005). Accordingly, relapse prevention is a 
primary goal of treatment in FEP.  Relapse following an initial psychotic episode is 
associated both with subjective experiences of despair, hopelessness and lack of control as 
well an increased risk of developing treatment resistant symptoms (Birchwood & Spencer, 
2001).  Indeed, the proportion of patients who become treatment resistant or only partially 
responsive to antipsychotic medications increases several-fold (up to 30-60%) following the 
initial episode (Lieberman, 1999; Lieberman et al., 1993). Decreases in medication response 
during successive illness episodes, which may represent either illness progression or 
development of tolerance to antipsychotic treatment effects, have been shown to be 
accompanied by more residual positive symptoms, an increase in negative symptoms, as well 
as decreased levels of functioning (Lieberman et al., 1996). Research demonstrating that  the 
likelihood of illness chronicity increases with each subsequent episode highlights the 
importance of relapse prevention and clinical intervention early in the course of a psychotic 
illness (Wiersma, Nienhuis, Slooff, & Giel, 1998).  
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In FEP, increased likelihood of symptom remission has been found to be associated 
with patient characteristics upon treatment presentation including shorter DUP (Addington & 
Addington, 2008b; Emsley et al., 2006; Emsley et al., 2007; Simonsen et al., 2007), female 
sex (Szymanski et al., 1995), later age at onset (Malla et al., 2006; Simonsen et al., 2007), 
better premorbid adjustment (Addington & Addington, 2008b; Malla et al., 2006), and lower 
baseline symptom levels (Addington & Addington, 2008b; but not Emsley et al., 2006; 
Novick et al., 2007). On the other hand, clinically useful predictors of long-term relapse risk 
have been difficult to determine (Bradford et al., 2003). However, variables during the course 
of treatment including medication adherence and substance abuse have shown significant 
associations with both risk of relapse and likelihood of symptom remission.  
Medication nonadherence is one of the largest impediments to achieving optimal 
symptom outcomes (Nasrallah & Lasser, 2006) and is one of the strongest factors associated 
with relapse in schizophrenia (Davis, 1975; Fenton et al., 1997; Kane, 1999). High rates of 
medication discontinuation have been reported in early psychosis, with approximately 60% 
of individuals becoming nonadherent within the first year of treatment (Coldham, Addington, 
& Addington, 2002; Mojtabai, Lavelle, Gibson, & Bromet, 2003; Mojtabai et al., 2002). 
Furthermore, poor medication adherence during the first 6 months after an individual‟s initial 
presentation has been shown to strongly predict poor medication adherence throughout the 
first 2 years after treatment, and is associated with an episodic course of illness and 
involuntary readmission (Verdoux et al., 2000).  In sum, a large proportion of individuals 
receiving treatment for psychotic disorders will become nonadherent to their medication 
regimes shortly after initial treatment, reducing the likelihood of symptom remission and 
increasing the risk of relapse. 
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Substance use disorders (SUDs) are also associated with failure to achieve symptom 
remission (Lambert et al., 2005), as well as a significantly increased risk of relapse which 
remains after controlling for medication adherence (Hides, Dawe, Kavanagh, & Young, 
2006; Malla et al., 2008; Sorbara, Liraud, Assens, Abalan, & Verdoux, 2003; Wade et al., 
2006). As many as half of patients receiving treatment for FEP will have a SUD (Addington 
& Addington, 2007; Lambert et al., 2005; Wade et al., 2006), with higher rates among 
younger clients, male clients, and those who are unemployed (Wade et al., 2005).  Substance 
abuse during recovery from FEP is also associated with disengagement from treatment 
(Schimmelmann et al., 2006). Wade and colleagues (2007) found in a 15-month prospective 
follow-up that individuals with heavy SUD had significantly poorer symptom and functional 
outcomes as compared to individuals with no SUD as well as compared to individuals with 
mild SUD, after controlling for the effects of sex, DUP, and medication adherence. This 
highlights the importance of SUD screening for all individuals entering care for early 
psychosis, and recommends timely intervention to educate clients about the risks associated 
with persistent substance use. 
Interventions targeting symptom remission and relapse. 
 Interventions which facilitate treatment engagement during the critical period and 
address barriers to symptom remission following an initial psychotic episode have the 
potential to make considerable impact on an individual‟s recovery trajectory. There are a 
number of cognitive-behavioral interventions that have now shown promise in reducing acute 
symptom levels (Lewis et al., 2002a; Lewis et al., 2002b; Tarrier et al., 2004),  improving 
attitudes towards antipsychotic medications (Uzenoff, Perkins, Hamer, Wiesen, & Penn, 
2008), and reducing cannabis use (Edwards et al., 2006) in early psychosis. Psychosocial 
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interventions aimed at reducing rates of relapse and rehospitalization in FEP have had less 
success. Individual cognitive behavior therapy has shown minimal efficacy in reducing 
relapse and hospitalization (Penn, Waldheter, Perkins, Mueser, & Lieberman, 2005). 
However, some multimodal (Gleeson et al., 2009) and family therapies (Zhang, Wang, Li, & 
Phillips, 1994) have reported benefits in relapse prevention.  
In sum, cognitive-behavioral therapies and other psychosocial interventions during 
the critical period have the potential to improve outcomes and facilitate the goal of timely 
symptom remission and effective illness management strategies. Relapse prevention and 
symptom remission are central goals in early intervention due to their association with illness 
course and a range of social and functional goals. In the next section, factors impacting social 
and functional recovery will be explored in more depth. 
Maximizing social and functional recovery. 
A final central goal of early intervention is improving functional outcomes and 
subjective experiences fundamental to the notion of „recovery.‟ In addition to freedom from 
persistent psychotic symptoms and symptomatic relapse, additional essential components of 
recovery from psychotic illnesses include satisfaction with life and suitable functioning in 
everyday life (Harvey & Bellack, 2009). However, a majority of individuals with early 
psychosis experience significant social and functional impairments which persist even after 
symptoms remit (Gupta et al., 1997; Robinson et al., 2004; Tohen et al., 2000). Whereas 
most individuals recovering from a first psychotic episode who function well are free from 
symptoms, a large proportion of individuals who experience a symptomatic remission fail to 
meet functional recovery standards (Wunderink, Sytema, Nienhuis, & Wiersma, 2009). 
Indeed in studies examining recovery trajectories, reported rates of functional recovery 
 12 
(including social, occupational, and independent living goals) are consistently lower than 
rates of symptomatic remission (Cassidy et al., 2009; Crumlish et al., 2009; Emsley et al., 
2006; Menezes et al., 2009; Petersen et al., 2008; Whitehorn, Brown, Richard, Rui, & 
Kopala, 2002; Wunderink et al., 2009).  
Social and occupational functioning. 
A wide array of measures of social and occupational functioning have been 
developed, and these include both subjective and objective measures. Notably, however, 
subjective measures (including ratings of feelings, thoughts and views on one‟s situation) and 
objective measures (i.e. facts about the situation which can be objectively and unequivocally 
assessed) of social and functional outcomes have shown only weak correlations (Priebe, 
2007). Whereas the low association between objective situations and subjective appraisal has 
led some to discredit subjectively-assessed status in psychotic disorders, these discrepancies 
may fluctuate with the illness course and provide important information about recovery 
experiences. For instance, Priebe and colleagues (Priebe, Roeder-Wanner, & Kaiser, 2000) 
found that although a sample of first-admitted schizophrenia patients had favorable objective 
indicators of quality of life in comparison to both in- and out-patients with chronic 
schizophrenia, the first-admitted patients endorsed lower subjective quality of life than both 
of the other groups. The authors suggest that these findings may reflect the recency of illness 
onset for individuals with FEP who have not yet had time to adapt to distressing symptoms 
and changes in life circumstances. Furthermore, individuals operating at similar functional 
levels (i.e. engaging in the same amount of work or school activities) may be bothered 
differentially by symptoms, and may or may not derive a sense of fulfillment from their 
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occupational activities. Therefore both objective and subjective reports of functioning are 
important and should be contextualized accordingly.  
Quality of life, one of the most commonly utilized constructs used to discuss social 
and functional status, is typically assessed using measures with both subjective and objective 
components. Reduced quality of life has been reported for individuals who have recently 
experienced a first psychotic episode  in comparison to non-clinical control samples using 
both subjective and objective evaluations (Addington, Young, & Addington, 2003b; Law et 
al., 2005). Among individuals with FEP, poor quality of life has been found to be associated 
with high levels of negative (Browne et al., 2000; Ho, Nopoulos, Flaum, Arndt, & 
Andreasen, 1998; Sim, Mahendran, Siris, Heckers, & Chong, 2004) and depressive (Law et 
al., 2005; Priebe et al., 2000; Sim et al., 2004) symptoms, with negative symptoms typically 
showing stronger associations with objective indices and depressive symptoms showing 
stronger associations with subjective indices (Górna, Jaracz, Rybakowski, & Rybakowski, 
2008; Malla et al., 2004). This is supported by Cassidy and colleagues‟ (2009) finding that 
symptom remission as defined by remitted positive symptoms alone did not significantly 
predict objective functioning, however when severity of negative symptoms was added, 
predictive validity increased. Thus, not only may social and functional outcomes show 
considerable heterogeneity deriving from differences between subjective and objective 
means of assessment, but different outcome measures may be impacted differentially by 
symptoms and premorbid factors, particularly by negative symptoms. For instance, in a 
review of early intervention studies for FEP, Malla and colleagues (2005) identified the 
following predictors of poor vocational adjustment: poor premorbid adjustment, negative 
symptoms at initial assessment, concurrent psychotic and negative symptoms, and poor 
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global cognitive functions. Likewise, predictors of social and community functioning 
included negative symptoms, premorbid adjustment, medication adherence, residual 
symptoms, and cognitive functions. And Siegel and colleagues (2006) found that overall 
functioning in FEP (including social, vocational and community functioning) was predicted 
by level of education and level of functioning at intake in addition to positive, negative and 
depressive symptoms at intake. 
Difficulties in social and occupational functioning in early psychosis may be 
explained by a number of experiences common to FEP in addition to persistent symptoms. 
Individuals recovering from an initial psychotic episode frequently have reduced social 
networks (Grant, Addington, Addington, & Konnert, 2001; MacDonald, Hayes, & Baglioni, 
2000), which may result from losing touch with old friends due to concerns of real or 
perceived stigma, as well as a desire to distance oneself from harmful lifestyles or activities 
(MacDonald, Sauer, Howie, & Albiston, 2005). Furthermore, there is some evidence that 
social cognitive impairments widely observed in individuals with more chronic illness 
courses (including impaired theory of mind, affect recognition and social cue perception) are 
present at the time of the first episode (Addington, Penn, Woods, Addington, & Perkins, 
2008; Bertrand, Sutton, Achim, Malla, & Lepage, 2007; Pinkham, Penn, Perkins, Graham, & 
Siegel, 2007). Finally, individuals recovering from an initial psychotic episode frequently 
experience disruptions in work or school functioning at the time of illness onset.  
Unemployment rates are significantly higher for individuals recovering from FEP than in a 
comparable general population (Killackey, Jackson, Gleeson, Hickie, & McGorry, 2006), the 
consequences of which include increased reliance on other sources of support (i.e. family 
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and/or public welfare), downward social drift, and loss of momentum in the development of 
occupational interests and development during early adulthood.  
These facets of social and occupational functioning are therefore central aspects of 
recovery in early psychosis. Both financial strain as well as the size and quality of one‟s 
social network have shown independent contributions to objective functional outcomes in 
FEP (Mattsson, Topor, Cullberg, & Forsel, 2008). Employment status has been associated 
with self-reported (Sim et al., 2004) and clinician-rated (Turner et al., 2009) quality of life  in 
FEP, as well as quality of life and self-esteem among individuals diagnosed with 
schizophrenia (Marwaha & Johnson, 2004). Furthermore, social support has shown strong 
associations with overall functioning in FEP (Erickson, Beiser, Iacono, Fleming, & Lin, 
1989; Górna et al., 2008), and strong support networks may impact other positive aspects of 
functioning, including medication adherence (Rabinovitch, Bechard-Evans, Schmitz, Joober, 
& Malla, 2009).  Therefore re-establishing social, work, and family relationships are a crucial 
step towards functional recovery in FEP (Edwards & McGorry, 2002).  
Subjective experience of recovery. 
In addition to quality of life and related social and occupational goals, there are other 
subjective experiences in the critical period that are important to assess in evaluating 
recovery status. On the one hand, this includes relief from negative emotional sequelae 
related to one‟s illness. Individuals with recent-onset illnesses may experience feelings of 
loss or disruption in their life, self-blame and guilt, worries about the reactions of friends and 
family members to their illness, and the fear and reality of social stigma (Miller & Mason, 
2005; Tarrier, Khan, Cater, & Picken, 2007). Given the prevalence of traumatic experiences 
accompanying FEP (Conus, Cotton, Schimmelmann, McGorry, & Lambert, 2007; Mueser & 
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Rosenberg, 2003), symptoms of PTSD, depression, social anxiety disorder, low self esteem 
and suicidality are all too common (Addington, Addington, & Patten, 1998; Birchwood et al., 
2006; Morrison, Frame, & Larkin, 2003).  
On the other hand are components described by Mays (2004) as comprising 
„psychological recovery‟, a concept distinguished from the aforementioned concepts of 
„clinical‟ or „social‟ recovery and defined as the “process of developing ways to understand 
and manage psychotic experiences and regain some sense of structure in one‟s life” (Mays, 
2004 p. 247). Indeed, there is some evidence that psychological well-being (a multi-
dimensional construct pertaining to feelings of autonomy, environmental mastery, personal 
growth, and self-acceptance) may be lower for individuals with FEP than for matched peer 
comparison groups (Uzenoff et al., in press). Accordingly, subjective experiences fostered in 
recovery include adaptation to one‟s illness (Jackson, McGorry, & Edwards, 2001a), 
increased feelings of hope and empowerment (Brown, Rempfer, & Hamera, 2008), building a 
positive personal and social identity, and becoming active in one‟s own recovery (Mays, 
2004).  
Interventions targeting social and occupational outcomes and subjective 
experiences of recovery. 
A number of psychosocial interventions have shown promise in impacting aspects of 
functional recovery in FEP. An open trial of Jackson and colleagues‟ Cognitively Orientated 
Psychotherapy for Early Psychosis (COPE) was associated with significant benefits in a 
measure of adaptation to illness (Jackson et al., 1998; Jackson et al., 2001b). Cognitive-
behavioral therapies have also been associated with  reduced experience of traumatic 
sequelae following a first episode of psychosis (Jackson et al., 2009) and decreased 
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suicidality and  improvements in hopelessness and quality of life (Power et al., 2003). The 
Graduated Recovery Intervention Program (GRIP), a cognitive-behavioral therapy program 
designed to facilitate functional recovery in early psychosis, has shown preliminary benefits 
in social functioning and goal attainment (Waldheter et al., 2008). And with respect to 
objectively assessed functioning, targeted vocational interventions have been associated with 
positive vocational outcomes, including increased employment rates and job longevity 
(Killackey, Jackson, & McGorry, 2008; Major et al., 2009). 
Functional remission. 
Unlike the consensus-definition of symptom remission, there is no agreement on what 
might define „functional remission,‟ nor a gold standard assessment for measuring functional 
outcomes (Mausbach, Moore, Bowie, Cardenas, & Patterson, 2009). One approach (e.g. 
Lambert et al., 2006) focuses primarily on objective markers and defines functional 
remission as at least six months of full- or part-time vocational functioning (i.e. employment 
or involvement in school activities) along with independent living. Alternately, Harvey and 
Bellack (2009) suggest that both objective and subjective evaluations of productive activities, 
residential and self-maintenance activities, and social relationships comprise essential 
domains of functioning to be considered as criteria for functional remission. Likewise, 
Liberman and Kopelowicz (2002) suggest a definition of functional recovery including 
independent living, social engagement with peers and subjective satisfaction with life, along 
with the central recovery aims of resilience and ability to cope with life stressors.  Each of 
these approaches reflects a unique definition of functional recovery, and is accompanied by 
limitations related to the subjective and/or objective measurements involved. One notable 
tradeoff is that although objective measures usually boast good face validity, they tend to be 
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more susceptible to ceiling effects and are slower and more difficult to change (Priebe, 
2007).  
Beyond establishing domains included in a remission definition, there is an additional 
challenge involved in specifying the level of functioning required for remission. For instance, 
whereas designating a „healthy range‟ of functioning is difficult because it requires a variety 
of value judgments about the types of interactions and involvements one should have with 
one‟s environment, a definition emphasizing return to premorbid functioning is complicated 
by the fact that oftentimes premorbid functioning itself may have been impacted by the 
illness prodrome (Harvey & Bellack, 2009). And finally, in determining the time frame for 
functional remission, it is necessary to consider the fact that attaining and maintaining 
functional gains might require a longer time period than does symptom remission, given the 
differential responsiveness of negative and cognitive symptoms to antipsychotic medications, 
both of which have shown to significantly predict a variety of social and functional outcomes 
(Dickerson et al., 2008; Mueser, Douglas, Bellack, & Morrison, 1991; Robinson et al., 2004). 
Finally, efforts to define functional remission have gone hand in hand with attempts 
to define a broader concept of recovery that incorporates both symptom and functional 
components (Liberman, 2002; Torgalsboen & Rund, 2002).  In this model, a UCLA group  
developed a definition of recovery derived from an aggregated body of empirical research 
including components generally supported by the first-hand experience of a panel of 
consumers, practitioners, and researchers (Liberman, Kopelowicz, Ventura, & Gutkind, 
2002). Components of this recovery concept include symptom remission, vocational 
functioning, independent living, and social relationships over a 2 year period.  However, 
across the literature examining global outcomes in FEP, various definitions of recovery have 
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been adapted. Some have used single established scales (including the Role Functioning 
Scale, Clinical Global Impression Scale, Social and Occupational Functioning Assessment 
Scale, and Strauss-Carpenter Scale) as a proxy for global outcome and/or recovery  (Lucas, 
Redoblado-Hodge, Shores, Brennan, & Harris, 2008; Menezes et al., 2009; Whitehorn et al., 
2002; Whitty et al., 2008), whereas others have used Andreasen et al.‟s (2005) consensus 
symptom remission criteria in addition to a set of a priori functional goals (such as paid or 
unpaid full- or part-time employment, involvement in school or head, independent living, 
ability to perform day-to-day living tasks without supervision, and social interactions outside 
the family at least once per week) (Lambert et al., 2006; Robinson et al., 2004). Still others 
have used the consensus remission criteria in addition to an established proxy scale of 
functioning (i.e. the Groningen Social Disabilities Schedule) (Wunderink et al., 2009), or 
idiosyncratic symptom and functional criteria (Petersen et al., 2008; White et al., 2009). 
Predictors of combined symptom and functional recovery include baseline negative 
symptom levels (Petersen et al., 2008; White et al., 2009; Whitty et al., 2008), DUP 
(Robinson et al., 2004; White et al., 2009; Whitty et al., 2008; Wunderink et al., 2009),  years 
spent in education (Whitty et al., 2008), premorbid adjustment (Lucas et al., 2008; White et 
al., 2009), baseline social role functioning (Wunderink et al., 2009), baseline medication 
adherence (Petersen et al., 2008), and cognitive functioning (Robinson et al., 2004). It should 
be noted, however, that it is difficult to interpret these findings given the heterogeneity of 
recovery definitions specified. Notably, rates of achieving both symptom and functional 
remission have generally been lower than those of achieving either symptomatic or 
functional recovery alone (Bertelsen et al., 2009; Lambert et al., 2006; Petersen et al., 2008; 
Robinson et al., 2004; Wunderink et al., 2009).  
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Summary: rationale and aims for early intervention. 
Early intervention aims to reduce duration of untreated psychosis, facilitate symptom 
remission, prevent relapse and treatment resistance, and improve social and functional 
outcomes, including a subjective experience of recovery. Reducing DUP has shown 
associations to improvements in both symptom and functional outcomes, highlighting the 
importance of early identification of psychotic illnesses and swift engagement in treatment. 
Relapse prevention and symptom remission are central goals in early intervention due to their 
association with illness course and a range of social and functional goals. There is a strong 
body of evidence suggesting that adherence to medication regiments and abstinence from 
substance use decreases the likelihood of relapse and poor illness course during the critical 
period. Therefore, fostering positive attitudes towards treatment and medications through 
psychoeducation and other psychosocial interventions during the critical period is an 
essential treatment goal. Furthermore early intervention is needed to help individuals with the 
tasks of social and functional recovery that often persist once symptoms have remitted. The 
subjective experience of recovery includes building adaptive coping skills in the light of 
illness-related stressors and losses, and helping individuals to re-engage with the tasks of 
daily life that frequently have been disrupted.  
Therefore, early intervention is called for based on a firm base of evidence linking 
treatment in the critical period to improved outcomes. But it is also based on an imperative 
from the research and consumer communities (i.e., from clients with early psychosis) to 
ameliorate suffering and further a model of care in which there is both the possibility and 
expectation of recovery. Treatment of FEP has previously been beleaguered by systemic 
problems in standard psychiatric care including delays in initial treatment, traumatic 
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experiences in the process of hospitalization, and poor treatment engagement and continuity 
of care (Edwards & McGorry, 2002; Garety & Rigg, 2001; Mueser & Rosenberg, 2003; 
Norman & Malla, 2001; Yung, Organ, & Harris, 2003). These concerns highlight the 
potential for service changes to greatly improve the standard of care for early psychosis. 
State of Early Intervention Treatment Programs for Early Psychosis 
Early intervention in psychosis has seen increased specialization and continues to 
emerge as a treatment modality defined by unique treatment models and techniques 
(McGorry, 2004; Owen, 2003). International clinical practice guidelines for the treatment of 
early psychosis have now been established, and these emphasize the key principles of early 
identification/detection, community-wide education, phase-specific programs of care, family 
involvement in care, and the responsible use of antipsychotic medications along with 
psychosocial interventions (IEPAWG, 2005).  At present, changes in service delivery to meet 
these principles have been heralded primarily by the development of specialized treatment 
centers and programs around the globe. These programs are unique in that they target many 
of the issues that are particularly problematic among young individuals experiencing 
psychosis through a variety of therapeutic approaches, emphasizing both symptomatic and 
functional recovery.  
Early intervention services in general are distinguished from standard care by both the 
structure of their services and by their content (McGorry, 2004). They focus on early 
detection and phase-specific treatment and take the form of treatment centers, service 
initiatives, and research programs dedicated to providing comprehensive services to young 
people and their families. Some estimate that close to 200 such efforts are underway 
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worldwide (IEPA, 2008; McGorry, Killackey, & Yung, 2007a). This treatment model and the 
evidence base for it will be examined in the next section. 
The multi-element treatment model. 
Multi-element treatment centers provide multiple services under one roof, offering 
comprehensive psychosocial and pharmacological interventions from dedicated first-episode 
clinics. Most multi-element programs adhere to an assertive case management model and 
prescribe low doses of atypical antipsychotic medications as front-line pharmacological 
treatment, in keeping with international treatment guidelines. Other treatment elements, 
including individual, group and family therapy, are offered to varying extents within different 
programs. Some multi-element programs have an additional goal of reducing DUP through 
community education and early detection initiatives. 
 The Early Psychosis Prevention and Intervention Centre (EPPIC) in Australia, one of 
the best-established and empirically evaluated multi-element treatment centers, is one of few 
such centers to incorporate a first-episode dedicated inpatient unit in addition to mobile 
assessment services, in- and out-patient case management, and individual, group and family 
therapy (McGorry, Edwards, Mihalopoulos, Harrigan, & Jackson, 1996). The Prevention and 
Early Intervention Program for Psychosis (PEPP) (Malla, Norman, McLean, Scholten, & 
Townsend, 2003) (which also includes inpatient services) and Calgary Early Psychosis 
Treatment Program (EPP) (Addington, Leriger, & Addington, 2003a) in Canada are 
additional examples of established early intervention centers. 
Comprehensive care may also be delivered via multi-element models of community 
care, in which specialized early psychosis services are offered as supplements to treatment as 
usual at generalized mental health care clinics, or as assertive outreach components in health 
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care systems in which no such services previously existed. Among models of community 
care, the OPUS trial in Denmark has developed an integrated treatment consisting of an 
enriched assertive community treatment (ACT) program, individual or group social skills 
training, and individual and family psychoeducation that has been rigorously evaluated in a 
randomized controlled trial (Jorgensen et al., 2000). Other programs, such as the Lambeth 
Early Onset (LEO) Team (Craig et al., 2004) and the Croyden Outreach and Assertive 
Support Team (COAST) (Kuipers, Holloway, Rabe-Hasketh, & Tennakoon, 2004) in the 
U.K. have developed similar treatments in the community using the assertive outreach 
model. The Swedish Parachute Project (Cullberg, Levander, Holmqvist, Mattsson, & 
Wieselgren, 2002) is a collaboration among multiple psychiatric clinics to implement 
comprehensive early psychosis services including individual and family therapy and 
overnight crisis homes as an alternative to hospitalization. And the Early Treatment and 
Identification of Psychosis (TIPS) Project (Johannessen, Larsen, McGlashan, & Vaglum, 
2000; Johannessen et al., 2001) in Norway and Denmark investigated whether supplementing 
multi-element care with early detection and community outreach efforts was associated with 
better long-term outcomes. (For further description of many of these programs, see Edwards, 
Harris, & Bapat, 2005; Edwards & McGorry, 2002; Penn et al., 2005). 
Across the literature, „early intervention‟ can inform the development of services with 
the following different aims:  a) preventing the emergence of psychosis through pre-
psychotic interventions, b) detecting  hidden morbidity in the community by identifying 
untreated cases of the disorder, and c) improving outcomes in people with established 
psychosis by facilitating and consolidating recovery (Singh, 2007). Although considerable 
research is emerging in the service of evaluating the first two aims, the present study focuses 
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primarily on the evidence base for treatments targeting the final aim alone. Accordingly, in 
this study, the phrase “early intervention” refers to intervention early after the emergence of 
psychosis; that is, treatment early in the course of an identified psychotic illness aimed at 
secondary prevention. 
Empirical evidence. 
Multi-element models of early intervention for psychosis have been included in 
several empirical reviews to date. Penn and colleagues‟ (2005) review of psychosocial 
interventions for FEP identified benefits associated with multi-element treatment in a wide 
range of symptom and functional outcomes, including symptom reduction and/or remission, 
improved quality of life and social functioning, low rates of inpatient admissions, less time 
spent in the hospital, decreased substance abuse, fewer self-harm behaviors, and reduced 
trauma secondary to psychosis and hospitalization. The authors caution that these results 
pertain primarily to one-year outcome evaluations, and that due to the uncontrolled design of 
most trials evaluated, findings should be interpreted with caution. 
Malla and colleagues‟ (2005) review found that in uncontrolled studies, rates of 
remission between 75-85% have been reported for specialized early intervention, although 
they note that these rates are similar to those observed for individuals treated in routine care 
among the studies they reviewed. Most studies in this review reported significant 
improvements in positive, negative, depressive, and anxiety symptoms, with change in 
negative symptoms more limited than that reported for positive symptoms. Malla and 
colleagues conclude that specialized early intervention is associated with modestly superior 
benefits including high rates of remission, better control of symptoms, and greater adherence 
and retention in treatment, as well as various benefits related to satisfaction, quality of life, 
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and broadly defined functional outcomes. They found less evidence of differential benefits 
for vocational outcomes in programs that did not specifically target this domain. 
In a meta-analysis, Harvey and colleagues (2007) examined psychosocial 
interventions for FEP including both multi-element programs as well as well-defined specific 
psychosocial treatments across multiple sites and studies. This analysis found benefits in both 
symptom and functional domains for adjunctive psychosocial interventions. For individuals 
receiving enriched interventions, including those attending a multi-element treatment 
program for at least 6 months, the mean effect sizes for reduction of positive, negative, and 
overall symptom levels as well as functional improvement at follow-up, were significantly 
greater for enriched intervention than for standard care.   
Since these reviews, multi-element treatment centers for early psychosis and models 
of community care have been consistently associated with positive and negative symptom 
reduction and/or remission in randomized controlled trials (Petersen et al., 2005a; Petersen et 
al., 2005b; Petersen et al., 2008; Thorup et al., 2005) and uncontrolled pre-post trials 
(Cocchi, Meneghelli, & Preti, 2008). Other comparisons (Cullberg et al., 2006; Garety et al., 
2006; Rosenbaum et al., 2005) have reported no differences between the specialized 
interventions and parallel control groups. Benefits for multi-element treatment have also been 
reported in improved quality of life and social functioning (Cocchi et al., 2008; Garety et al., 
2006; Petersen et al., 2005b) and decreased substance abuse (Lambert et al., 2005; Petersen 
et al., 2005a; Petersen et al., 2005b). 
Although relapse rate comparisons are difficult given varying definitions of relapse 
(i.e. hospital admission, increase in symptoms, etc.), relapse rates reported from early 
intervention trials (29-36%) have been significantly lower than those reported by centers 
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providing non-specialized care to FEP clients (over 50%) and in the broader literature for 
first-episode clients treated in routine care (55-70%) (Addington, Addington, & Patten, 
2007a; Malla et al., 2008).  While these data suggest the benefits of early intervention, it is 
difficult to say to what extent these improved outcomes reflect the effectiveness of the 
specific interventions used above and beyond the other salutary correlates of earlier treatment 
(Addington et al., 2007a). 
Reduced inpatient and emergency service utilization translates to cost-savings for 
many of these health care systems. The introduction of the PEPP program was accompanied 
by a significant mean reduction in costs per case with respect to hospital bed use and hospital 
emergency service usage, however analyses failed to confirm that these savings could be 
attributed specifically to the introduction of the early intervention services (Payne, Malla, 
Norman, Windell, & Brown, 2006). Likewise, mean direct costs for individuals treated in the 
experimental arm of the Parachute Project were approximately half those for individuals 
treated in the prospective comparison group (Cullberg et al., 2006). Since the Parachute 
group had substantially increased outpatient service usage but decreased inpatient service 
usage, this suggests that the savings reflect the extent to which inpatient hospitalizations 
drastically increase treatment costs (though it should be noted, however, that indirect costs 
were not assessed in that study). Cost savings related to reductions in inpatient service usage 
have also been reported for early intervention services at EPPIC (Mihalopoulos, McGorry, & 
Carter, 1999) as well as through the OPUS trial of assertive community care (Bertelsen et al., 
2008), for which there was evidence that the savings were directly related to reduced use of 
supported housing. 
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A recent economic evaluation of EPPIC provides one of the most dramatic 
demonstrations of cost savings. In a matched historical control group design, a cohort of 65 
individuals was followed for eight years after initial treatment via either EPPIC or general 
mental health services (Mihalopoulos, Harris, Henry, Harrigan, & McGorry, 2009). EPPIC 
treatment was associated with superior outcomes in several clinical and functional domains at 
one-third of the annual treatment cost of standard public mental health services. Individuals 
receiving care through EPPIC were significantly more likely to be in symptomatic remission 
than the matched cohort, and 56% were involved in paid employment in the past two years as 
opposed to 33% of controls. Indeed, mental health care costs are incurred not only by 
psychological and psychiatric services, but across sectors including primary healthcare, 
school systems, and juvenile justice and social service agencies. Costs to the family of the 
individual in treatment include direct costs (e.g. travel) as well as indirect costs, including 
care givers‟ ability to work and the family‟s and patient‟s lost earnings (Costello, Copeland, 
Cowell, & Keeler, 2007). Further economic evaluations of early intervention programs are 
currently underway and may be essential in swaying policy for future service development 
(McCrone & Knapp, 2007).  
Overall, multi-element treatment for early psychosis has been associated with 
improvements in symptom and functional domains as well as relapse prevention. In 
reviewing the empirical evidence base, there are several methodological concerns with 
should be taken into consideration. First, the durability of gains needs to be further explored. 
Caveats noted in earlier reviews (i.e. Penn et al., 2005) regarding the predominance of 
publications reporting only short-term outcomes are becoming less salient, as benefits 
conferred by multi-element programs beyond one year have been reported (Cassidy, Schmitz, 
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Norman, Manchanda, & Malla, 2008; Craig et al., 2004; Garety et al., 2006; Joa et al., 2008; 
Malla et al., 2008; Petersen et al., 2005a; Thorup et al., 2005).  Bertelsen and colleagues 
(2008) recently reported on 5 year-outcomes of the OPUS trial, following the 3-year period 
after which the enhanced early intervention services were withdrawn, and found that the 
previously noted benefits in symptom reduction and global functioning improvement 
(Petersen et al., 2005a) were no longer present.  However, in comparison to individuals 
treated in routine care, those who received the early intervention services still had an 
advantage in percentage utilizing supported housing as well number of hospital days over the 
course of the study. Overall, this suggests that while enhanced treatment improved functional 
outcomes, there was little symptomatic improvement that endured once services were 
withdrawn. Likewise, individuals followed 1-2 years following discharge from EPP 
continued to demonstrate functional improvement, as well as improvement in negative 
symptoms, despite no further improvement in positive symptoms (Addington & Addington, 
2008a).  
One of the longer term evaluations of multi-element treatment has come from EPPIC, 
wherein approximately 8 years after treatment initiation, individuals treated at EPPIC had 
lower levels of psychotic symptoms, were more likely to be in remission, and had a more 
favorable course of illness than did a historical control comparison group treated in 
community care (Mihalopoulos et al., 2009). Longer term follow-ups from other initiatives 
will be required to better characterize the impact of treatment transitions following specialty 
care in the critical period. 
Secondly, as noted in other recent reviews of this area (Edwards et al., 2005; Penn et 
al., 2005), much of the research on multi-element programs is based on quasi-experimental 
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designs comprising historical and parallel comparison groups, or on single-group designs, 
which track the progress of one group over a specified period of time. Recent publication of 
data from the OPUS (Bertelsen et al., 2008; Petersen et al., 2005a; Petersen et al., 2005b; 
Thorup et al., 2005), LEO (Craig et al., 2004; Garety et al., 2006; Power et al., 2007), and 
COAST (Kuipers et al., 2004) trials represents a promising trend in the scientific evaluation 
of multi-element programs. Nonetheless, there has been little randomized controlled research 
in this area (Marshall & Lockwood, 2003; Marshall & Rathbone, 2006) and the body of 
findings needs to be interpreted with caution.   
Another important consideration in evaluating these programs is the varying degree to 
which interventions are standardized and replicable (e.g. Craig et al., 2004; Kuipers et al., 
2004), which may pose a threat to the external validity of the findings. For one, treatments 
offered as part of randomized clinical trials may fundamentally differ in type or quality from 
those offered in routine clinical settings (e.g. Slade, Holloway, & Kuipers, 2003). Likewise, 
the use of assessors who are not blinded to treatment condition (e.g. Petersen et al., 2005a; 
Petersen et al., 2005b) may be associated with biased ratings on a variety of clinical 
outcomes and should be noted with caution. Additionally, services vary in type, quality and 
quantity between these various multi-element programs. As Birchwood comments (author's 
reply to Manchanda, Norman, & Malla, 2004), the focus in this area of early intervention has 
largely been on engagement of clients and on the initial challenges of service development 
and provision within existing healthcare systems: it is perhaps most accurate to say that these 
programs have largely served as a vehicle for intervention, rather than comprising 
interventions themselves. Indeed, with the exception of EPPIC, which has tested several 
specific component interventions in controlled trials (see Edwards, Hinton, Elkins, & 
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Anthanasopoulos, 2003; Edwards, Wade, Herrman-Doig, & Gee, 2004; Jackson et al., 2001b; 
Power et al., 2003), few of the programs report utilizing treatment manuals or fidelity 
assessments for the therapies delivered within their multi-element programs. This only 
contributes to difficulties in replicating the services offered by these programs. 
Finally, the breadth of services offered by EPPIC and other initiatives highlights the 
potentially complex mechanisms through which multi-element services confer benefits. It is 
yet unclear which „key ingredients‟ are responsible for improved outcomes, including 
functional gains that are frequently more elusive. Harvey and colleagues (2007) speculate 
that the superior effect sizes for positive symptom improvement in enriched care above and 
beyond those reported in standard care in their meta-analysis may be explained by any 
number of mechanisms specific to multi-element programs, including better treatment 
adherence, better engagement early in treatment, greater involvement or inclusion of family 
in treatment, increased attention to specific personal or social goals, or increased attempts to 
reduce drug and alcohol use through case management and therapy. Notably Petersen and 
colleagues (2005a) report that the significant advantage in positive symptom reduction at 
both 1 and 2 years for individuals in integrated treatment versus standard care in the OPUS 
trial was not accounted for by differences in use of antipsychotic drugs, although individuals 
in the integrated condition were less likely to discontinue treatment for at least a month than 
were individuals in standard care. A variety of mechanisms may also be proposed for 
reduction in substance use, which has been observed in the OPUS (Petersen et al., 2007), 
EPP (Addington & Addington, 2001b), and EPPIC (Lambert et al., 2005) programs in the 
absence of a specialized substance abuse intervention.  
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There is some evidence that increased attention and resources devoted to treatment 
engagement may be a potent element of comprehensive treatment for early psychosis. In 
narrative accounts, individuals recovering from first-episode psychosis have articulated a 
preference for spending time with people who had similar experiences, who understood 
them, and with whom there was a mutual trust (MacDonald et al., 2005). Therefore a 
treatment environment geared towards the particular developmental needs of a first-episode 
population may be more attractive to these individuals and successful in engaging them in 
treatment. Additionally, because individuals with early psychosis often have reduced social 
networks and are more likely to count service providers in their support networks 
(MacDonald et al., 2000), there is a substantial potential for mental health providers to 
impact early treatment attitudes including attitudes towards medication and substance use 
behaviors. Good treatment engagement additionally allows for more consistent and frequent 
assessments, which can increase providers‟ ability to  monitor clinical status, including 
changes in medication side effects or suicidality (Addington, Williams, Young, & 
Addington, 2004b; IEPAWG, 2005). 
Of particular interest are findings that multi-element treatment is associated with 
improvements in negative symptoms, given the fact that such symptoms are typically more 
treatment refractory. A historically controlled investigation of EPPIC found sustained 
improvement in negative symptoms in the EPPIC group that was not observed for controls, 
although levels of depressive symptoms remained relatively low and constant for both 
groups, suggesting that the reduction in negative symptoms was not due to a decrease in 
depression (although this study did not control for doses or duration of antipsychotic 
medication treatment) (McGorry et al., 1996).  Harvey and colleagues (2007) reported in 
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their meta-analysis that enriched interventions  reduced negative symptoms by a greater 
magnitude than standard care. And perhaps most noteworthy, in the OPUS RCT, negative 
symptoms showed significantly greater reductions in the integrated treatment group as 
compared to standard care (Petersen et al., 2005a). Notably, the integrated group also 
received significantly lower doses of second generation antipsychotics. Limitations of the 
OPUS findings include the fact that raters were not blinded and negative symptom ratings 
only demonstrated moderate inter-rater reliability. Thorup et al (2005) conducted an analysis 
on the 2-year follow-up data in this trial to examine the influence of different components of 
the integrated treatment on clinical outcomes, including the significant reductions in negative 
symptoms. The findings revealed important information on the relative efficacy of a variety 
of treatment components, including medication, social skills training, and multifamily 
groups.  However, none of these treatment elements could independently account for the 
combined effects of the integrated treatment program as a whole.   
The above findings highlight the difficulties posed by the current nosology by which 
schizophrenia is defined, and the likelihood that primary negative symptoms (or those which 
are core symptoms of the disorder and of insidious onset) and secondary negative symptoms 
(or those which may be attributed to extrinsic factors such as medication side effects, social 
deprivation or isolation, or psychological reactions to psychotic symptoms) (Carpenter, 
Heinrichs, & Wagman, 1988) may be differentially impacted by treatment (Arango, 
Buchanan, Kirkpatrick, & Carpenter, 2004). Thorup (2005) suggests that the negative 
symptom reductions in the OPUS findings are likely attributable to improved treatment 
planning, including lower doses of second generation antipsychotics and reduced incidences 
of inpatient readmission, whereas Harvey et al. (2007) speculate that increased attention to 
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individuals‟ social and environmental conditions, including social contacts, family relations, 
and educational or vocational pursuits may be responsible for the negative symptom 
reduction they reported. Mechanisms through which multi-element treatment may impact 
either primary or secondary negative symptoms are still unclear.  However,  evidence is also 
consistent with the possibility that a multimodal, comprehensive approach to treatment may 
indeed produce the greatest improvements in patient outcomes than isolated medical or 
psychosocial interventions alone (Lenroot, Bustillo, Lauriello, & Keith, 2003; Marder, 2000). 
Challenges in multi-element service development. 
The call for further research in multi-element treatment includes attempting to 
replicate services and generalizing findings beyond the extant programs. However, as 
highlighted in the review of findings in this paper, multi-element treatment thus far has 
flourished predominantly in a handful of Western European nations as well as in Australia, 
Canada, and the UK. The extent to which multi-element interventions can be widely 
implemented and integrated into existing mental health care systems around the globe is 
determined in large part by local political environments and healthcare infrastructures. And 
even in regions where the necessary institutional supports are in place, incorporating new 
treatments, policies, and service structures can pose a multitude of challenges. A closer look 
at systemic factors that facilitate comprehensive early intervention services, as well as those 
that serve as barriers, helps contextualize the body of published findings in this field and 
highlights challenges for future research. 
Supportive system factors. 
Research in multi-element treatment has flourished in several regions in which the 
government has dedicated funding and health care jobs to early psychosis care. The UK is an 
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exemplar of a nationalized health care system that has recently undergone restructuring with 
an emphasis on first-episode treatment with the result of substantially increased services. 
Following a 2000 National Health Service policy release, which identified mental health 
provision as one of the nation‟s top 3 priorities, a plan for the development of 50 new early 
intervention services over the course of several years was released. These service needs were 
influenced heavily by input from consumer advocacy groups that had identified a high level 
of dissatisfaction in services offered during the critical period (Joseph & Birchwood, 2005). 
Likewise, in Australia, state-directed initiatives have heralded significant increases in 
funding and services allocated to early intervention. For instance, the Early Intervention 
Worker initiative in Victoria allocated funds in each of the state‟s 21 geographically defined 
mental health regions for a mental health clinician dedicated to the early identification and 
treatment of serious mental disorders, including FEP, in young adults aged 16-25. 
Access to epidemiological (or nearly epidemiological) samples of individuals seeking 
care for early psychosis is another systemic factor which has made research and service 
development in multi-element treatment possible. For instance, Australia has an integrated 
mental health service that mandates 24-hour, 7-day per week crisis intervention, assertive 
community care and acute inpatient care when needed.  Consequently, in regions that are 
home to specialized early intervention services and in which there are few private 
practitioners, such as the EPPIC catchment area of Melbourne, nearly all individuals 
presenting for treatment for a first psychotic episode will receive specialized care (Conus et 
al., 2007).   
Whether a clinic‟s catchment area is served by either one or multiple mental health 
care providers may change the illness severity and demographics of individuals presenting 
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for care. Indeed this is a source of selection bias in many studies, in that the most ill patients 
in a system where there are multiple providers may be funneled to specialty care, which 
therefore leads to poorer outcomes and higher attrition. Other considerations include the size 
of the center, as smaller or mid-size units have been found to work more effectively for this 
type of specialized mental health care than larger centers (Malla et al., 2007; Marshall, 
Lockwood, Lewis, & Fiander, 2004).  
Systemic barriers in the US. 
These concerns and others need be taken into consideration in furthering research and 
treatment agendas in the US, owing to political and organizational characteristics that 
distinguish this country from the others previously discussed. Although the US is home to 
approximately one fifth of the 30 early psychosis programs listed in an online directory by 
the IEPA (IEPA, 2008), at present no publications regarding early intervention services have 
originated from the US. Whereas service development in other English-speaking nations has 
formed an essential research base upon which successive efforts can be launched, there are 
significant differences between the mental health care policies and financing of other 
Westernized nations and those of the US that pose challenges to generalizing findings and 
disseminating practices. 
The US is alone among developed nations in lacking a universal health care system. 
Although the country does have significant publicly funded components (namely Medicaid 
and Medicare) which cover approximately one quarter of the population, another 16% of the 
population (or 47 million people) are uninsured (Census Bureau, 2006). As most people in 
the US are covered by a health insurance plan related to employment, the increasing number 
of uninsured individuals represents people who cannot obtain health insurance through their 
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employer or are unable to afford individual coverage. An additional proportion of uninsured 
people in the US include individuals under the age of 30 who don't believe they need to 
purchase health care, and others who are eligible for Medicaid but have not applied. 
Young people with psychotic disorders are at a particular disadvantage with regard to 
being insured. The likelihood of being covered by health insurance rises with income, and 
unemployment rates are significantly higher for individuals experiencing FEP than in a 
comparable general population (Killackey et al., 2006). Indeed, data from a large 
epidemiologic sample of FEP patients (N=525) found that 44% of this sample was uninsured, 
with 39% receiving private insurance and another 15% receiving either Medicaid or 
Medicare (Rabinowitz et al., 1998). In this sample, there was a trend wherein private 
insurance was associated with a greater likelihood of being hospitalized within 3 months of 
the onset of psychosis, being admitted voluntarily, and being admitted to a community 
hospital rather than a public hospital. In short, disparities in insurance coverage place 
individuals with early psychosis at a potentially significant disadvantage to receiving timely 
care. 
Indeed, individuals with psychotic disorders have traditionally been among the most 
disadvantaged groups with respect to insurance coverage and service utilization. There is a 
gap between healthcare need and service utilization for individuals with severe mental 
illness, with one national survey indicating that three-fifths of such individuals did not 
received specialty psychiatric care within a 12-month period (McAlpine & Mechanic, 2000). 
As compared to individuals being treated for primary mood or anxiety disorders, individuals 
with schizophrenia and other psychotic disorders are less likely to belong to a health plan of 
any kind (i.e. either private or public) after controlling for sex, ethnicity, education, and 
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employment, and are nearly twice as likely to receive public assistance (i.e. Medicaid or 
Medicare) (Compton, Weiss, Phillips, West, & Kaslow, 2006). Therefore, lack of insurance 
serves as a primary barrier to receiving appropriate services (McAlpine & Mechanic, 2000). 
US healthcare differs in other important ways from the majority of the Western 
nations that have piloted multi-element early intervention programs. For one, the US offers 
primary medical care through the three different (and at times competing) major specialty 
disciplines of general internal medicine, family medicine, and general pediatrics, rather than 
a single primary medical specialty (i.e. the „general practitioner‟ model)  (Halvorsen, 2008). 
This fragmentation poses challenges to broad-based educational interventions directed to 
non-psychiatric medical professionals aimed at identifying early psychosis and reducing 
treatment delays. Additionally, because data on the means by which individuals with early 
psychosis enter treatment has been gathered primarily from countries with nationalized 
healthcare systems and differently structured primary care provision, we still have a poor 
idea of what these pathways to care look like in nations like the U.S. 
Another system-related factor in the US is the increasing privatization of community 
mental health centers, wherein services are contracted to not-for-profit agencies rather than 
provided directly by states or government municipalities. As a result, these centers are 
typically cost-conscious and less able to justify dedicating resources to employing clinical 
psychologists and other providers best trained in direct service provision of some of the 
component elements of comprehensive treatment for early psychosis, including cognitive-
behavioral therapy for psychosis, medication adherence interventions, and treatments for 
comorbid conditions (Roe, Yanos, & Lysaker, 2006).  In sum, lagging research progress on 
the multi-element treatment model in the US is further understood when taking into 
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consideration the multiple indices on which mental health care policy and service provision 
differ in the US from many of the countries with well-established early psychosis initiatives. 
Our challenge remains, however, to work within this infrastructure to contribute to the 
knowledge base regarding best practices and to act upon our commitment to a recovery 
model.  
Summary: state of treatment for early psychosis. 
A rapidly expanding body of research in multi-element interventions for early 
psychosis marks an international effort to address inadequacies in standard mental healthcare 
for this population, as well as a resounding affirmation of a recovery model which 
acknowledges the potential to ameliorate suffering and disability with timely intervention.  
Research to date in adjunctive psychosocial interventions for FE psychosis suggests that such 
treatments may help patients across stages of recovery on a number of different outcomes.  
Comprehensive multi-element interventions show promise to positively impact short-term 
outcomes following an initial episode of psychosis, such as clinical status and social 
functioning, as well as likelihood of relapse and hospital readmission.  It is unclear how long 
these benefits persist, although there is limited data suggesting that functional improvements 
may outlast symptomatic improvement. 
Multi-element treatment centers have typically utilized a quasi-experimental or pre-
post design to evaluate a program‟s effectiveness, as has the majority of published research 
in this area. As Edwards and colleagues (2005) discuss, randomized experimental research 
with multi-element programs poses both logistical and ethical dilemmas, including 
community concerns regarding withholding comprehensive services from patients and 
negative feelings of staff who are providing control conditions.  With pre-post designs, one 
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cannot control for factors such as spontaneous remission and the role of therapeutic attention.  
Thus, findings from uncontrolled trials must be interpreted with caution.  Nevertheless, data 
emerging from interventions across multiple sites and countries have been encouraging and 
the evidence base at present certainly does not recommend against future attempts to model 
early psychosis care according to international guidelines for timely and comprehensive 
treatment. In order for policy and ideology to meet with respect to early intervention in 
psychosis, recovery-oriented interventions must be pushed to the forefront of treatment 
outcome research, especially in the US.     
Overview of Current Study and Hypotheses 
The purpose of this study is first, to describe the baseline characteristics and course of 
clinical and functional outcomes of an early psychosis cohort treated in a US-based multi-
element treatment center, and second, to examine predictors of functional outcome one year 
after initiation of specialized treatment. The study will provide a naturalistic prospective 
follow-up of individuals with early psychosis consecutively treated at the Outreach and 
Support Intervention Services (OASIS) clinic affiliated with the University of North Carolina 
(UNC) Hospitals. Founded in 2005 (by Diana Perkins, MD, David Penn, PhD and Barbara 
Smith, LCSW), this clinic provides services to adolescents and young adults who are 
experiencing early psychosis, or who are at risk for developing psychosis. OASIS is a 
comprehensive multi-element treatment program, offering phase-specific treatments tailored 
to first-episode psychosis. Services are provided on- and off-site, including; psychiatric 
assessment, medication management, psychosocial assessment, individual therapy, family 
support, multifamily group, educational group, group therapy, case management, assertive 
outreach, crisis services, and recreational activities. OASIS is one of few multi-element 
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programs offered in the United States that is specially designed to meet the needs of young 
people experiencing early psychosis. The primary study aims are as follows: 
Aim 1: Descriptive analysis of a US-based multi-element treatment center for 
early psychosis. 
The first aim of this study is to characterize the population accepted for treatment at 
OASIS during its first three years of operation (June 2005-June 2008) on demographic 
variables including age at referral, sex, race, employment or schooling status, marital status, 
living situation, DUP, and insurance coverage. This information is collected routinely 
through the clinic and maintained in both paper charts as well as an electronic database. Only 
individuals referred for first-episode psychosis (including both affective and non-affective 
psychoses), rather than for prodromal symptoms, will be included in analyses. 
These data will be compared descriptively to published samples at other established 
first-episode clinics including EPPIC (i.e. Conus et al., 2007; Henry et al., 2007), EPP (i.e. 
Addington & Addington, 2001b; Addington & Addington, 2008b; Addington et al., 2003a; 
Addington et al., 2004b; Addington et al., 2003b), and PEPP (i.e. Malla et al., 2002a; Malla 
et al., 2002b; Malla et al., 2003).  To evaluate the representativeness of the sample treated at 
OASIS, a subsample of the study cohort will be compared to a sample treated in other North 
Carolina mental health care settings matched on age (18-30), insurance status 
(Medicaid/Medicare and self-pay), primary diagnosis (schizophrenia and other psychotic 
disorders) and number of previous hospitalizations. These data, available publicly from the 
NC Department of Mental Health (DMH), are part of routine outcome data collected 
statewide for individuals receiving Medicaid/Medicare/state-funded treatment. These two 
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samples will be compared on baseline global functioning and substance use as well as 
demographic variables including sex, ethnicity, living situation, and employment status.  
Aim 2: One-year longitudinal evaluation of symptom, social and vocational 
outcomes for individuals treated at OASIS. 
  The second aim of this study is to examine whether the treatment offered at OASIS is 
associated with improvement on core indices of recovery.  Data collected at one year will be 
used to assess within-subject change on outcome variables as well as the percentage of 
individuals in the sample meeting important recovery benchmarks, including symptom 
remission, functional remission, and combined symptom and functional remission. 
Additional outcomes reported will include number of nights hospitalized over the course of 
one year, and the percentage of participants disengaging from treatment prematurely (i.e. 
against treatment team recommendation). Individuals who disengage from treatment 
prematurely will be compared to those still in treatment on baseline clinical and demographic 
characteristics. Finally, billing records will be examined to determine service utilization 
(including initial assessment, medication management, individual therapy, group therapy, 
community support, case management, phone contact, and family services) over the one year 
period. Exploratory correlation analyses will be conducted to examine the relationship 
between service utilization and various indices of functional outcome. It is hypothesized that 
comprehensive OASIS treatment will be associated with improvement in each of the 
outcome domains, including symptomatic and functional recovery.  
Aim 3: Examination of predictors of one-year functional outcomes.  
The final aim of the current study is to examine predictors of functional outcome in 
early psychosis. This aim builds on previous findings suggesting that lower symptom levels, 
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and particularly symptom remission early in the course of treatment, may impact functional 
outcomes. The goal is to examine the relationship between symptom remission during the 
initial phases of treatment and functional outcomes, as well as the impact of medication 
adherence and substance use during treatment on these functional outcomes. Functional 
outcomes will include subjective experiences of recovery and both objective and subjective 
measures of social and occupational functioning. Based on their association to functional 
outcomes in the literature, the following predictors will be entered as covariates into the 
regression model: sex, age, and DUP. It is hypothesized that failure to achieve symptomatic 
remission, poor medication adherence, and substance use over the course of treatment will 
negatively influence social and functional outcomes, controlling for variables with known 
prognostic value, including sex, age, and DUP.
  
METHOD 
Participants 
OASIS serves adolescents and young adults aged 16-36 who have been treated for 
psychosis (i.e. have been taking antipsychotic medications) for no more than three years, as 
well as previously unmedicated individuals who have been ill for up to 5 years. OASIS also 
provides services to individuals who are experiencing prodromal symptoms and may be at 
risk of developing psychosis. Referrals to OASIS come from several sources, primary among 
which are the inpatient and emergency treatment services of the UNC Hospital System. 
Additional referral sources include the UNC counseling center, family members, and 
community mental health providers. OASIS serves clients living within approximately one 
hour‟s driving distance of the clinic site. Priority is given to residents of the two most 
immediate local communities (Orange and Durham counties); residents from other counties 
may receive services based on initial assessment and the program's capacity to provide 
services. For patients in need of emergency psychiatric care or inpatient hospitalization, 
OASIS clinicians work with the patient and his or her family to facilitate coordination of care 
including disposition planning upon hospital discharge. When possible, patients in need of 
inpatient hospitalization are treated within the UNC Healthcare system.  
 The first point of contact with OASIS involves a phone screening, conducted by the 
clinic director or a clinical social worker. At this point a brief history is obtained.  
Exclusionary criteria for acceptance into the program include head trauma, mental 
retardation, and pervasive developmental disorders. Individuals accepted for treatment are 
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then scheduled for an intake appointment. For the purposes of this study, all individuals 
accepted for treatment for early psychosis (i.e. meeting diagnostic criteria for schizophrenia, 
schizophreniform disorder, schizoaffective disorder, bipolar disorder, major depressive 
disorder with psychotic features, brief psychosis/brief psychotic episode, and psychosis not 
otherwise specified) were included in analyses. Individuals determined to be experiencing 
prodromal symptoms at the time of intake were excluded from all proposed analyses. A 
cohort of individuals accepted for treatment at OASIS (i.e. those who completed a baseline 
visit) in the time period from the clinic‟s opening (June 2005) through June 2008 (N=163) 
were analyzed.  
Setting 
 OASIS is a comprehensive, multi-element center for the treatment of early psychosis. 
The clinic is operated by the UNC Health Care System, a not-for-profit integrated healthcare 
system, owned by the State of North Carolina and based in Chapel Hill, NC.  The OASIS 
program was developed by a multidisciplinary team of specialists in the Department of 
Psychiatry at the UNC School of Medicine (Diana Perkins, MD, Barbara Smith, LCSW, and 
David Penn, PhD). Consistent with the program‟s emphasis on community outreach and 
accessibility, the clinic is located separate from the primary hospital complex in an easily 
accessible office suite. The clinic is located on the local public transportation bus line and has 
ample free parking. OASIS has a clinical capacity of approximately 100 patients.  
The mission of OASIS is to foster successful recovery from early psychosis and to 
increase public understanding of psychotic disorders. Key program aims are to provide early 
identification and treatment of psychotic disorders, prevent relapse and hospitalization, 
minimize disruption in individuals‟ lives, and support individuals in the workplace, school 
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and relationships. Within the community, OASIS has the aims of educating the community 
and other providers to recognize early psychosis and the importance of early treatment, to 
provide educational opportunities for mental health professionals, and to provide access to 
state of the art clinical research programs. Services are provided in a youth-friendly 
environment with a strong focus on sustained engagement in treatment. 
The clinical staff at OASIS includes licensed clinical social workers, psychiatrists, 
and psychologists. Every patient is assigned a primary clinician (a licensed social worker) 
who provides clinical services and case management based on individual need.  Interventions 
range from engagement techniques (i.e. making phone calls to engage reluctant or withdrawn 
clients) to various aspects of case management to providing individual supportive and 
cognitive-behavioral therapy. All clients are assessed for eligibility to receive community 
support, which broadly encompasses assistance in living skills with an objective of helping 
recipients achieve autonomy and stability. Services are frequently provided in the community 
or at the client‟s home in addition to in the office.  
Each patient at OASIS also receives psychiatric assessment and medication 
management from a psychiatrist. Antipsychotic medications are typically prescribed in low 
doses in keeping with recommendations for the treatment of early schizophrenia with a goal 
of positive symptom remission. Patients and their families are provided education about 
medication and medication side effects, and patients are monitored closely for the emergence 
of side effects, including weight gain and metabolic side effects. Patients are weighed at each 
visit and lipids and glucose monitored semi-annually. Additionally, diet and exercise 
counseling is routinely provided by the OASIS psychiatrist. A change in antipsychotic 
medication is considered if the patient is not having a robust clinical response, or if 
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intolerable side effects emerge. Comprehensive treatment plans are developed by the 
psychiatrist in collaboration with the OASIS treatment team, who meets weekly to discuss 
cases. 
Family engagement and support are important aims of the comprehensive treatment 
offered at OASIS. Family psychoeducation is typically provided upon initiation of treatment 
in sessions with the patient‟s keyworker or psychiatrist. Family members may meet 
individually with members of the treatment team for additional education and support. 
Multifamily groups are held on a bi-monthly basis, and single family sessions are offered at 
the family‟s request. 
Other time-limited groups lasting for 8-12 weeks are offered periodically depending 
on interest and need. Topics include psychoeducation, healthy lifestyle habits, stress 
management, substance abuse and social skills training. In addition to these opportunities for 
peer support and interaction, OASIS offers social activities to clients that aim to mitigate 
feelings of isolation and to give clients a safe environment to practice social skills. Outings 
such as bowling trips, pizza socials, and seasonal parties are held throughout the year. These 
activities help to engage clients in services as well as to foster a sense of community while 
facilitating integration back into normative social roles that may have been interrupted.  
Finally, a certified substance abuse counselor provides substance abuse assessment, 
individual therapy and leads a group following the integrated dual diagnosis modality of 
treatment. These targeted substance abuse interventions were developed after the first several 
years of clinic operation and therefore were not available to a large proportion of the study 
sample. During the initial years of clinic operation, substance abuse was addressed in 
psychoeducation provided in groups, individual therapy, and psychiatrist visits.  
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Measures 
During the OASIS intake appointment, an extensive psychosocial history is obtained. 
At this point, baseline objective and subjective clinical data is gathered.  Data is collected 
routinely at six month intervals. The schedule of assessments is found in Table 1. 
Demographic and clinical information. 
Demographic information collected includes age, sex, race, marital status, county of 
residence, living situation, health insurance status, and school or employment status 
(including whether the client is employed and/or in school, and how many hours are spent in 
each). This information was verified and/or updated at each subsequent visit. Clinical 
information obtained at baseline includes an estimate of the following information via 
interview with the patient, the patient‟s family members, and other sources of collateral 
information (i.e. hospital discharge summaries): date of first psychotic symptoms (i.e. 
symptoms designated in Criterion A of DSM-IV diagnosis for schizophrenia), date of first 
contact with a health professional for psychotic symptoms, and the date the patient first took 
at least one dose of an antipsychotic medication for his/her psychotic symptoms. This 
information was used to estimate DUP. A primary diagnosis was entered for each visit 
beginning at baseline, as well as the status of the diagnosis (i.e. active, partial remission, or 
remission). Secondary and medical diagnoses were also noted.  
Hospitalizations and service utilization. 
Days hospitalized over the preceding six-month period were assessed at each 
evaluation time-point following baseline. Service utilization was determined from a billing 
audit. Number of visits was recorded for each of the following types of services: initial 
 48 
assessment, individual therapy, group therapy, community support, case management, phone 
contact, family therapy, and medication management.  
Symptoms. 
The expanded Brief Psychiatric Rating Scale (BPRS-E) (Lukoff, Liberman, & 
Nuechterlein, 1996) is a 24-item scale developed from the Brief Psychiatric Rating Scale 
originally developed by Overall and colleagues (Overall & Gorham, 1962).  This measure 
assesses symptom levels based on clinical observations during the interview and subjects‟ 
verbal report of symptoms in the 2 week period leading up to the interview. Each item is 
rated on a 7-point scale, rated from 1 (not present) to 7 (most severe). Per Lukoff  and 
colleagues (Lukoff et al., 1996), ratings of 2-3 indicate a nonpathological intensity of a 
symptom whereas ratings of 4-7 indicate a pathological intensity of that symptom. 
One of the most widely used measures of symptom levels, the BPRS has been shown 
to be highly sensitive to change (Mortimer, 2007). Varying four-factor solutions have been 
suggested by several different confirmatory and exploratory factor analyses (Dingemans, 
Linszen, Lenior, & Smeets, 1995; Mueser, Curran, & McHugo, 1997; Van der Does, 
Linszen, Dingemans, Nugter, & Scholte, 1993; Velligan et al., 2005; Ventura, Nuechterlein, 
Subotnik, Gutkind, & Gilbert, 2000). In this study, a four-factor solution including Positive 
Symptoms, Activation, Negative Symptoms, and Depression/Anxiety (Velligan et al., 2005) 
was used due to previous demonstrations of its validity for a recent-onset psychosis 
population as well as across the illness course (Kopelowicz, Ventura, Liberman, & Mintz, 
2008). Acceptable internal consistency has been reported for these factors (Positive α=.67, 
Activation/Mania α=.68, Negative α=.79, Depression/Anxiety α=.78) (Velligan et al., 2005) 
and this was replicated in the present study (see Appendix for factor composition).  
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Symptom remission was defined according to criteria proposed by Andreasen et al. 
(2005). In order to be considered „remitted,‟ individuals must have ratings of mild or less (≤ 
3) simultaneously on all of the following BPRS items: Grandiosity (Item 8), Suspiciousness 
(Item 11), Unusual thought content (Item 15), Hallucinatory behavior (Item 12), Conceptual 
disorganization (Item 4), Mannerisms/posturing (Item 7), and Blunted Affect (Item 16). 
Additionally, symptom levels must stay below the severity threshold for six months in order 
to meet the remission criteria. Therefore, in order to meet remission criteria at six months, 
individuals must have met severity criteria at both the baseline and six-month visits. 
Participants were classified as either “in symptomatic remission” or “not in symptomatic 
remission” at six months and at one year. 
Substance use. 
Alcohol and illicit drug use was assessed with the Alcohol Use Scale (AUS) and Drug 
Use Scale (DUS), respectively (Drake, Mueser, & McHugo, 1996).  The AUS and DUS were 
developed to assess and track substance use among individuals with severe mental illness.  
On each scale, individuals receive a rating of 1-5, corresponding with diagnostic criteria for 
abstinence, use without impairment, abuse, dependence, or dependence with 
institutionalization.  Ratings are made based on the previous six months, and are based on 
client self-report, clinician observation, and information from collateral sources. The AUS 
and DUS have demonstrated good psychometric properties (Drake et al., 1996).  In 
longitudinal studies of individuals with severe mental illness living in the community, test-
retest reliability for both scales has been excellent (i.e., close to 100%), and inter-rater 
reliability has also been good (kappa = .80-.95). In this study, presence of substance abuse at 
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each evaluation point was defined by any AUS/DUS items rated  ≥ 3. Absence of AUS/DUS 
items rated  ≥ 3 was classified as „substance abuse absent.‟ 
Medication adherence. 
Medication adherence was assessed via a single-item rating made by the psychiatrist 
at each visit. The clinician was asked to rate the frequency with which the patient takes 
his/her medication using the following prompt: “How many days have you missed your 
medication in the past month?” The number of days of missed medication was then coded 
according to the following scale: 1=always/almost always adherent (76-100% of the time), 
2=usually adherent (51-76% of the time), 3=sometimes adherent (26-50% of the time), 
4=never/almost never adherent (0=25% of the time). At each time point, individuals with 
ratings of 1 were classified as „adherent‟, and those with ratings of 2 through 4 were 
classified as „nonadherent.‟ 
Global functioning. 
Measures of both objective and subjective global functioning were used.  The Global 
Assessment of Functioning (GAF) scale (American Psychiatric Association, 2000) was used 
to measure objective global functioning. The GAF is a unidimensional rating of global 
functioning based on psychological, social, and occupational criteria made by a clinician. 
Ratings are made on a scale from 1-100 and are divided into 10 ranges of functioning, with 
higher ratings indicating better functioning. The description of each 10-point range in the 
GAF scale has two components covering symptom severity and functioning. A rating is made 
within a particular decile if either the symptom severity or the level of functioning falls 
within that range, and the final GAF rating always reflects the worse of the two. In this study, 
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the period rated was the past week. This scale is associated with adequate reliability and has 
been reported to be highly sensitive to change (Mausbach et al., 2009). 
 Subjective global functioning was assessed using the Outcome Questionnaire (OQ 
45.2) (Lambert et al., 1996). The OQ 45.2 was designed to measure change following 
psychological interventions and includes items relevant to three domains of mental health: 
symptom distress, interpersonal relations, and social role performance. The OQ 45.2 is a self-
report measure that includes 45 items and requires subjects to rate their feelings on a five-
point Likert scale ranging from 0 to 4 (i.e. 0=never, 4=almost always).  After reverse scoring 
nine items, a total score and three subscale scores are calculated with the following ranges; 
Total Score=0-180 (clinical range= >63), Symptom Distress=0-100 (clinical range= >36), 
Interpersonal Relations=0-44 (clinical range= >15), Social Role=0-36 (clinical range= >12) 
(see Appendix for full scale and subscales). The OQ 45.2 has been shown to possess 
adequate stability, test-retest reliability, and internal consistency in populations of 
undergraduate students as in well as clinical samples (Lambert et al., 1996), and adequate 
internal consistency was demonstrated in this study as well (see Appendix). 
Role functioning and recovery. 
Both objective and subjective measures of recovery were used. The Role Functioning 
Scale (RFS) (Goodman, Sewell, Cooley, & Leavitt, 1993) was used to measure objective 
social and functional recovery. The RFS comprises four single rating scales for evaluating 
the functioning of individuals in specified areas of everyday life: Working Productivity, 
Independent Living and Self Care, Immediate Social Network Relationships, and Extended 
Social Network Relationships. The values on each of the four scales range from one, which 
represents a very minimal level of role functioning, to seven, the hypothetically optimal level 
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of role functioning, and each of the seven points on the scales is accompanied by a 
behaviorally defined description (See Appendix for full scale). The scale is designed to be 
completed following a standard intake interview and ratings are based on the patient's 
functioning in the week prior to the evaluation. The total score represents a Global Role 
Functioning Index with scores ranging from 4 to 28. The RFS has been found to have high 
internal consistency and adequate test-retest reliability (Goodman et al., 1993). Excellent 
internal consistency was demonstrated in this study as well (see Appendix). 
The Recovery Assessment Scale (RAS) (Giffort, Schmook, Woody, Vollendorf, & 
Gervain, 1995) was used to measure the subjective experience of recovery. The scale is 
composed of 41 items on which patients describe themselves using a five-point agreement 
scale (1=strongly disagree to 5=strongly agree) (see Appendix for full scale). This measure 
has been shown to be valid and reliable (Corrigan, Giffort, Rashid, Leary, & Okeke, 1999), 
and correlates with other measures of recovery (McNaught, Caputi, Oades, & Deane, 2007). 
This measure had excellent internal consistency in the current study (see Appendix).  
As previously noted, school or employment status (including whether the individual 
is employed and/or in school, and how many hours are spent in each) was documented by 
either the clinic director or primary clinician at each evaluation time point. The following 
levels of employment status were defined; unemployed, seeking employment, volunteer, 
work (1-10 hrs/wk), work (11-20 hrs/wk), work (21-30 hrs/wk), work (31-40 hrs/wk), and 
work (40+ hrs/wk). School status was recorded as a binary response (i.e. “Is the patient 
currently involved in school?” Yes or No) and clinicians were asked to document number of 
hours per week spent in school involvement. For the purposes of this study, individuals were 
considered to be working or attending school at least half-time if employment status was 21-
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40+ hours/wk or if the individual was involved in school activities for at least 20 hours per 
week.  
Given the lack of a widely accepted measure of functional remission, functional 
remission was defined in this study using face valid, objective criteria pertaining to social, 
occupational and independent living skills. Functional remission at each visit was defined by 
adequate to optimal role functioning (i.e. scores ≥ 6 on each of the four RFS subscales) and 
working or attending school at least half-time. As with symptomatic remission, participants 
were classified into two categories: „in functional remission‟ and „not in functional 
remission‟ at each visit. 
Data Analytic Plan 
The following steps were taken in analyzing the data for this study. First, a 
descriptive analysis of the OASIS sample was completed in order to characterize the study 
cohort. Baseline demographics and clinical characteristics of the OASIS sample were 
examined alongside those of a matched sample treated in other North Carolina mental health 
care settings.  
Next, within-subject change from baseline to one-year on symptom, social and 
vocational outcomes was examined using paired-sample t-tests. Effect sizes for paired data 
were calculated per the suggestion of Cohen (1988) (d = mean difference/standard deviation 
of the mean difference) and evaluated according to accepted standards: small (d = .20), 
medium (d = .50), and large (d = .80). Logistic regression analyses were used to test changes 
in proportions of individuals meeting criteria for symptomatic remission, functional 
remission, and other binary functional outcomes of interest. All of the aforementioned 
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analyses were conducted using PASW Statistics 18, Release Version 18.0.0 (SPSS Inc., 
Chicago, IL, USA).  
 Finally, a generalized estimating equations (GEE) approach (Liang & Zeger, 1986) 
was used to examine predictors of functional outcomes over time. GEE is an extension of the 
generalized linear model that is ideally suited for repeated measures data sets where 
unknown correlation is present.  GEE models are population-averaged (or marginal) models 
that allow the correlation of outcomes within an individual to be estimated and taken into 
account in the formula which generates the regression coefficients and their standard errors. 
This approach holds significant advantages over repeated measures analysis of variance, 
which can only be used with interval outcomes and in datasets in which there are equal 
numbers of observations for each subject (Katz, 2006). GEE can accommodate covariate-
dependent missing data and therefore is suited for a naturalistic longitudinal study such as 
this one. Effect sizes of explanatory variables are regression coefficients (B) for continuous 
variables and odds ratios (ORs) for categorical variables. 
In GEE, repeated measures for each outcome at each time period (i.e. baseline, six 
months and one year) are pooled to produce an estimate of the population-averaged effect of 
the predictors on each outcome. Each functional outcome (RFS scores, RAS scores, 
functional remission status, and work/school status) was modeled as a function of time, 
symptom remission status (in remission or not in remission), substance abuse status (present 
or absent), and medication adherence status (present or absent). These associations were 
adjusted for confounding factors by including sex and age of referral as time-invariant 
covariate factors. All GEE analyses were conducted using SAS 9.2 (SAS Inc., Cary, NC, 
USA). 
  
RESULTS 
Between the dates of June 1, 2005 and June 1, 2008, 405 individuals were phone-
screened by OASIS clinicians. Of these 405 individuals, 150 were referred out for meeting 
exclusion criteria (see Methods section) and 255 individuals were accepted for treatment (See 
Figure 1 for treatment flow diagram). The rate of referrals during the initial months of the 
clinic‟s operation was steady, resulting in meeting clinic capacity within the first 18 months 
of operation (see Figure 2). Of the 255 individuals accepted for treatment at OASIS, 31 
individuals did not attend an intake appointment (i.e. did not follow-up to schedule an 
appointment or no-showed a scheduled appointment). An additional 24 individuals had 
psychosocial intakes but never received a baseline assessment (10 of these individuals were 
consults and therefore did not receive baseline assessments, and an additional 14 individuals 
were lost to follow-up). Of the 200 individuals who received baseline assessments, 2% (n = 
4) were consults (i.e. did not receive ongoing care at OASIS) and 17% (n = 33) were 
accepted for monitoring at OASIS due to their clinical at-risk (i.e. prodromal) status. The 
remaining 163 individuals comprise the early psychosis cohort that was analyzed in this 
study.  
A total of 64 individuals (39% of the study cohort) were discharged prior to one year, 
31 of whom were discharged between baseline and six months. Two individuals discharged 
prior to six months later re-contacted the clinic and were readmitted prior to the one-year 
evaluation. In both cases, the individuals experienced a return or worsening of psychotic 
symptoms and contact was reinitiated by family members. Of the 64 individuals discharge
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before one year, 33% (n = 21) were refusing treatment at the time of discharge. Discharge 
reasons for individuals not refusing treatment (n = 43) included; geographic relocation (n = 
18), no longer appropriate for care at OASIS (i.e. too chronic or in need of more intensive 
services) (n = 10), return to work or school full-time (n = 6), preference for another provider 
(n = 6), program dissatisfaction (n = 1), probation violation/incarceration (n = 1), and death 
(n = 1).  
Because data collection occurred as part of routine care and was completed by full-
time clinicians, missing data were expected to occur due to both clinician factors (including 
failure to administer all assessments at each time point) as well as client factors (including 
refusal to complete self-report measures, failure to attend appointments on or near the six-
month or one-year study visits, and attrition). Missing data were examined on both a visit-
wise and measure-wise basis. The database was constructed such that all required assessment 
forms are generated simultaneously at the time a visit is manually established by a clinician. 
As a result, a visit only appears in the database if one of more of the outcome measures is 
completed at that time point, and any other required forms that are not completed will appear 
in the database as blank. At six months, visits were missing for 16 patients (i.e. 12% of 132 
expected visits), and at one year visits were missing for 14 patients (i.e. 12% of 116 expected 
visits).  
Additional missing data were observed within existing study visits. A systematic 
inspection of electronic study records was conducted for 25% of the study cohort in order to 
better characterize data missing measure-wise. Forty-two records were randomly selected 
and reviewed for the presence of 9 different assessments that were to be collected at each 
study visit. Among the 42 sets of records reviewed, an average of 66% of the generated 
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forms were complete in the database (i.e. 34% were left blank). Across visits for the entire 
study cohort, self-report measures (including the OQ and RAS, together comprising 
approximately 30% of all missing forms) were the most frequently missing outcome forms, 
and the most consistently collected outcome form was the GAF (which accounted for less 
than 1% of missing forms).  
Characterization of the OASIS Sample 
Sixty-seven percent of the study cohort was male, and 66% was Caucasian (see Table 
2). Mean age at the time of intake to the clinic was 23.1 years (SD = 4.5), with a higher mean 
age for females than males (F(1,161) = 3.24, ns). Most individuals (91%) had never been 
married and were living in private residences (91%). A majority (61%, n = 96) had private 
insurance at baseline, whereas 19% (n = 31) received public assistance via 
Medicaid/Medicare and 22% (n = 35) were uninsured (insurance status was not reported for 1 
individual, and 3 individuals reported both Medicaid/Medicare and private insurance). 
The most common diagnosis was schizophrenia, followed by psychosis NOS (see 
Figure 3).  At the time of intake, 29% (n = 47) of the study cohort carried a secondary 
diagnosis of active substance abuse (n = 31) or dependence (n = 16), with an additional 6% 
(n = 10) diagnosed with substance abuse or dependence in partial remission. These findings 
are consistent with AUS/DUS ratings taken at baseline.  Of the 122 individuals for whom 
AUS/DUS data were collected at baseline, 23% (n = 28) were abusing one or more 
substances at baseline, with cannabis and alcohol representing the most frequently abused 
substances.  
Information on duration of untreated psychosis (DUP) was only available for 76 
individuals in the study cohort. DUP for the study cohort ranged from 0 to 63 months, with a 
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mean DUP of 4.74 months (SD = 11.51, Mdn = 0, mode = 0). Over half of individuals for 
whom DUP data were available (53%, n = 40) had a DUP < 1 month, and an additional 28% 
(n = 21) had a DUP ≤ 3 months. Only 2 individuals had a DUP > 36 months.  Due to 
concerns regarding to the validity of DUP calculations, DUP was not used in successive 
analyses as initially proposed. 
Previous treatment and hospitalizations. 
A majority of individuals in the study cohort were referred from inpatient hospital 
units (35%) and outpatient hospital clinics (32%). Additional referrals coming from family 
members (14%), private practitioners (6%), a local transitional housing/employment program 
(4%), ER/crisis services (3%), the University counseling service (3%), and self-referrals 
(2%).  
Data on previous treatment and involvement with the correctional system was 
available for approximately 2/3 of the study cohort (n = 109).  Of these individuals, 71% had 
been in outpatient treatment for a psychiatric disorder prior to engaging with OASIS, 
however only 15% were receiving concurrent services outside of OASIS at the time of 
baseline. Individuals had a mean of 1.4 previous hospitalizations (SD = 1.29, Mdn = 1, mode 
= 1, range = 0-6).  Fifty seven percent of individuals had been hospitalized once, 13% had 
been hospitalized twice, and 12% had been hospitalized three times or more. Seventeen 
percent had never been hospitalized for psychiatric reasons. Six percent were under 
correctional supervision at the time of baseline, and 22% had prior arrests.  There were no 
significant differences in baseline symptom (BPRS total scores) or levels of global 
functioning (GAF) between individuals who had data on previous treatment and those who 
did not.  
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Medications and medication adherence. 
Medication data was recorded for 72% (n = 117) of the sample at baseline. Of these 
individuals, 86% (n = 101) were prescribed at least one atypical antipsychotic medication, 
and 9% (n = 10) were prescribed a second atypical antipsychotic medication. An additional 
4% (n = 7) of individuals with medication data at baseline were prescribed a first-generation 
antipsychotic medication. One individual (<1%) was prescribed a first-generation 
antipsychotic medication in addition to an atypical medication, and one individual (<1%) was 
prescribed two first-generation antipsychotic medications. 
Most frequently prescribed atypical antipsychotics were; olanzapine (n = 36), 
risperidone (oral) (n = 32), aripiprazole (n = 24), quetiapine (n = 8), ziprasidone (n = 8), 
risperidone (intramuscular) (n = 2), and clozapine (n = 1). The most common first-generation 
antipsychotic medications were haloperidol (n = 4), followed by perphenazine (n = 2), 
fluphenazine (decanoate) (n = 1), fluphenazine (oral) (n = 1), and haloperidol decanoate (n = 
1). Sixty individuals (51%) were prescribed at least one additional class of medications, with 
benzodiazepines being the most frequently prescribed class (n = 24), followed by SSRI 
antidepressants (n = 20), mood stabilizers (n = 17), other second generation (i.e. non-SSRI) 
antidepressants (n = 13), heterocyclic/MAO antidepressants (n = 5), vitamins (n = 4), other 
anxiety/sedative (i.e. non-benzodiazepine) medications (n = 1), and others (n = 14). One 
individual was not prescribed any medications. 
Of individuals prescribed antipsychotic medications, 91% (n = 76/84) were rated as 
adherent (i.e. scores of “1=always/almost always”, 76-100%) to their medication regiments. 
In cases where individuals were prescribed more than one antipsychotic medication, the 
lower adherence rating was used.  
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Sample representativeness. 
Aggregated data from the NC-TOPPS outcome monitoring program were examined 
in order to determine the characteristics of individuals treated for early psychotic disorders 
elsewhere in the state of North Carolina. Data collected during the period June 1, 2005 
through June 30, 2007 were extracted from the NC-TOPPS database for individuals 18 and 
older. Search criteria used to approximate an early psychosis cohort were: age ≤ 30 years, 
diagnosis classification of “Schizophrenia and other psychotic disorders,” and prior inpatient 
mental health admissions ≤ 1 (the criterion of one or fewer previous inpatient mental health 
admissions was selected based on findings that 74% of the OASIS study cohort fell into this 
same category). Additionally, data for the provider IDs assigned to UNC Hospital‟s 
Schizophrenia Treatment and Evaluation Program (STEP) clinic as well as OASIS were 
excluded from this query. This search identified a comparison sample of 1,440 individuals. 
For the purposes of this comparison, a subsample of individuals in the OASIS study 
cohort was selected based on the following criteria: insurance status of Medicaid/Medicare or 
self-pay, age ≤ 30 years. There were 55 individuals who met these criteria.  Of these 
individuals, data on previous hospitalizations was available for N=37 individuals, of whom 
59% (n = 22) had one or no previous hospitalizations. This subsample of individuals did not 
differ from the rest of the OASIS sample on age, sex, race, marital status, GAF score, 
percentage in labor force, history of prior arrest, correctional status, or substance abuse or 
dependence diagnosis at baseline. A significantly lower proportion of individuals in the 
subsample were living in private residences as compared to the rest of the OASIS sample 
(Fisher exact test, p<.05). 
 61 
 Demographic and baseline clinical characteristics for the subsample of individuals 
treated at OASIS as compared to individuals identified to approximate a first-episode 
psychosis sample elsewhere in the state of NC are presented in Table 3. Given the large 
difference in sample sizes, formal inferential statistics were not conducted. However, the 
pattern of data suggests that the OASIS sample had a higher GAF and included a greater 
proportion of White/Caucasian individuals than did the NC-TOPPS sample.   
One-year Outcomes 
Service utilization. 
Services offered at OASIS were classified into the following categories: initial 
assessment/interview, medication management, individual psychotherapy, group therapy, 
family therapy, multi-family group therapy, phone contact, and community support. Over the 
course of the initial year of treatment, individuals receiving care at OASIS had a mean of 
20.31 service contacts (SD = 20.24, Mdn = 13.00), with medication management and 
individual psychotherapy accounting for the most frequent types of services utilized, 
regardless of insurance status (see Table 4). Individuals with both Medicaid/Medicare and 
private insurance received the most services, however it should be noted that there were only 
3 individuals with this insurance status (including one individual with a total of 116 service 
contacts who fell over five standard deviations above the group mean total service 
utilization). Ninety-two percent of individuals in the study cohort received at least one 
medication management visit, 62% received at least one session of individual psychotherapy, 
51% received at least one session of family therapy, 33% received at least one session of 
multi-family group therapy, and 23% received at least one session of group therapy. Only 4% 
of the study cohort was billed for community support. 
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Exploratory analyses were conducted to examine the relationships between service 
utilization and symptom and functional outcomes at one year (see Table 5). Number of 
medication management sessions showed significant negative correlations with GAF scores 
and RFS total, Working Productivity, and Extended Social Network scores, as did total 
number of contact hours. Likewise, number of community support contacts showed 
significant negative correlations with GAF scores and RFS total, Working Productivity, and 
Independent Living scores. For all of these associations, as the number of contacts increased, 
severity or functioning level on these scales worsened. Number of individual psychotherapy 
sessions showed a significant negative correlation with OQ social role subscale scores (i.e. as 
number of contacts increased, distress on this subscale decreased) and a significant positive 
correlation with BPRS Depression/Anxiety subscale scores (i.e. as number of contacts 
increased, symptoms on this subscale increased in severity). Number of group therapy 
sessions showed significant positive correlations with OQ total, Symptom Distress, and 
Social Role scores, wherein as the number of contacts increased, distress on each of these 
scales increased.  These findings should be interpreted very cautiously, however, for two 
primary reasons: 1) they are exploratory in nature; 2) there was no effort to correct for 
conducting multiple correlations, thus any significant bivariate correlations may reflect Type 
I error. 
Hospitalization and involvement in the criminal justice system. 
Fifteen percent (n = 15/99) of the study cohort were hospitalized for psychiatric 
reasons during the first six months of treatment, and those hospitalized spent a mean of 13.67 
nights in the hospital (SD = 12.53, range = 3-54). Eighteen percent (n = 13/73) of the cohort 
had psychiatric hospitalizations between six months and one year, and those hospitalized 
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during this time period spent a mean of 9.92 nights in the hospital (SD = 5.00, range = 4-20). 
Complete hospitalization data for the entire study period was available for 70 individuals, 
27% (n = 19) of whom had been hospitalized for a mean of 13.84 nights (SD = 11.02, Mdn = 
11, range = 4-45) over the course of their first year of treatment. Overall, individuals were 
hospitalized for a mean of 3.76 nights (SD = 8.37, Mdn = 0, range = 0-45). Individuals with 
complete hospitalization data did not differ significantly from those with incomplete data on 
baseline demographic or clinical variables (including age, sex, DUP, symptom remission 
status, functional remission status, GAF, or private vs. not private insurance status).   
Six percent (n = 6/98) of individuals were arrested during their first six months of 
treatment, and there were no arrests reported between six months and one year. Eight percent 
(n = 8/96) were under correctional supervision during their first six months in treatment, and 
half of these individuals  remained under supervision for at least a portion of their second six 
months in treatment.  
Medication adherence and substance abuse. 
Prevalence of substance abuse in the overall study sample fell from 23% (n = 28/122) 
at baseline to 19% (n = 16/84) at six months and to 13% (n = 10/80) at one year. Likewise, 
for individuals with paired baseline and one year data (n = 67), substance abuse prevalence 
fell from 24% at baseline to 12% at one year, though there was no statistically significant 
change in likelihood of substance abuse from baseline to one year (OR = 0.48, 95% CI [0.22, 
1.05], p = .067).  
The percentage of individuals rated as adherent to their antipsychotic medication 
regiments decreased from 91% (n = 76/84) at baseline to 84% (n = 63/75) at six months, and 
was 85% (n = 61/72) at one year. For those with paired baseline and one year data (n = 49), 
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medication adherence fell from 90% at baseline to 86% at one year. There was no significant 
change in the proportion of adherent individuals from baseline to one year. Seventy-six 
percent of the sample (n = 32/40) were adherent to their medications at all three study visits. 
Changes in primary outcomes over one-year. 
One-year visits were established in the OASIS outcome database for 87 individuals. 
Individuals who were missing one year visits for any reason (including discharge, lost to 
follow-up, uncompleted forms, etc.) did not differ significantly from individuals with one 
year visits in age, sex, symptom remission status, functional remission status, or private vs. 
not private insurance status at baseline. Individuals with and without one year data also did 
not differ significantly on any baseline outcome measures. Baseline means for the entire 
sample, paired means for individuals with both baseline and one-year data, and 
corresponding significance tests and effect sizes are presented in Table 6.  
Symptoms, global functioning and experience of recovery. 
Significant symptom reduction from baseline to one year was observed on the BPRS 
total score as well as on the Positive symptoms, Activation, and Negative symptoms factors, 
with changes corresponding to small to medium effect sizes. There was no statistically 
significant change on the Depression/Anxiety factor. There was also a statistically significant 
improvement in GAF scores from baseline to one year, corresponding to a large effect size 
and a shift from serious symptoms or level of impairment to mild symptoms or level of 
impairment (American Psychiatric Association, 2000). 
Improvements in OQ scores from baseline to one year reached statistical significance 
for the Symptom Distress and Social Role subscales as well as for the total score. These 
improvements corresponded to medium effect sizes but failed to reach the reliable change 
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indices (RCIs) calculated by Lambert et al (2004) to denote clinically significant change on 
each (i.e. RCI for Total Score = 14 points; RCI for Symptom Distress = 10 points; RCI for 
Interpersonal Relations = 8; RCI for Social Role = 7). There were no statistically or clinically 
significant changes on the Interpersonal Relationship scores.  
It should be noted that in comparison to the sample for whom OQ data were available 
at baseline (n = 94) (who were within or close to the clinical range cut-off on total scores as 
well as subscale scores), individuals for whom OQ data were available at both baseline and 
one year (n = 29) fell below the clinical range on the total score and all subscale scores at 
baseline. Individuals showed trend level improvements on the RAS which were not 
significant.  
Role and occupational functioning. 
Scores on each of the four RFS items (Working Productivity, Independent Living, 
Immediate Social Network, and Extended Network) showed significant improvement from 
baseline to one year, corresponding to medium to large effect sizes. Change on the total score 
was also statistically significant and corresponded to a large effect size. Individuals were 
significantly more likely to have adequate to optimal role functioning across domains on the 
RFS (i.e. scores ≥ 6 on each item) at one year than at baseline (OR = 3.46, 95% CI [1.64, 
7.26], p = .001). Overall, 22% (n = 12/55) of the sample for whom paired data were available 
moved from not demonstrating adequate to optimal role functioning at baseline to doing so at 
one year, and only 2% (n = 1/55) moved from demonstrating adequate or optimal role 
functioning at baseline to not doing so at one year. 
Occupational status was examined with respect to time spent in work and or/school 
activities (see Table 7). Individuals were significantly more likely to be involved in school at 
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one year than at baseline (OR = 2.40, 95% CI [1.33, 4.33], p = .004), and significantly less 
likely to have no occupational involvement (i.e. neither work nor school involvement) (OR = 
0.42, 95% CI [0.24, 0.73], p = .002). Likewise, there was an increased likelihood of at least 
half-time occupational functioning between baseline and one year, but this change was not 
statistically significant (OR = 1.52, 95% CI [0.87, 2.67] , p = .14). Overall, 14% (n = 12/86) 
of the study cohort moved from not working or attending school at least half-time at baseline 
to doing so at one year, and 7% (n = 6/86) moved from working or attending school at least 
half-time at baseline to not doing so by one year.  
Symptom and functional remission. 
There was a significant increase in the proportion of individuals meeting symptom 
remission criteria as determined by severity only from baseline to one year (OR = 3.02, 95% 
CI [1.67, 5.47], p < .001) (see Table 8). Eighty-four percent (n = 48/57) of individuals met 
remission severity criteria at one or more study visits over the course of the year, and 63% (n 
= 36) experienced symptom remission for a duration of at least six months at some point 
during the study period. Fifty-seven percent of the cohort (n = 38/67) met both severity and 
time criteria for symptom remission at one year.  
There was also a significant increase in proportion of individuals meeting functional 
remission criteria from baseline to one year (OR = 3.63, 95% CI [1.16, 9.71], p = .025).  
Eighteen percent (n = 9/51) met functional remission criteria at one or more study visits over 
the course of the year, though only 8% (n = 4/51) were able to sustain this level of 
functioning for two consecutive study visits (six months and one year, in all cases). 
At both baseline and one year, whereas the majority of those in functional remission 
also experienced symptom remission, it was less common for those meeting symptom 
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remission criteria to also meet functional remission criteria (see Table 8). When symptom 
remission as determined by both severity and time was considered at one year (n = 50), 80% 
of those meeting functional remission criteria also met full symptom remission criteria, 
whereas 15% of those experiencing symptom remission also met functional remission 
criteria.  There was no significant increase in the likelihood of concurrently meeting 
symptom and functional remission criteria from baseline to one year.  
Predictors of Functional Outcomes 
Prior to conducting all predictor analyses, correlations between all independent 
variables and covariates were examined (see Table 9). In general, significant correlations 
were consistent with the wider literature. There was a significant correlation between age and 
sex , wherein older age at the time of referral was associated with female sex, as well as a 
significant correlation between substance abuse status and sex , wherein a status of 
„substance abuse present‟ was associated with male sex.  However, it is important to note that 
the absolute magnitude of these correlations is small and that this analysis did not correct for 
multiple comparisons. 
Using PROC GENMOD in SAS, GEE models were run using a repeated statement to 
specify within-patient clustering and an exchangeable working correlation matrix. For 
models predicting work/school status (working/attending school at least half-time versus not) 
and functional remission status (in remission versus not), a binary distribution and logit link 
function were specified. Across models, time was treated as a categorical factor with three 
levels (baseline, six months and one year) rather than a continuous covariate based on scatter 
plots indicating non-linear change on the dependent variables across the three time points. 
Symptom remission status, medication adherence status, and substance abuse status were 
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entered as 2-level categorical factors (i.e. “present” or “absent” for each variable). Model 
covariates included sex and mean-centered age. Additionally, Symptom Remission X Time, 
Medication Adherence X Time, and Substance Abuse X Time interaction terms were included 
in each model. 
Primary predictor analyses. 
In the model predicting RFS total scores, there was a significant main effect of 
symptom remission status (B = 1.39, SE = 0.52, p = .007), wherein individuals in symptom 
remission had significantly higher role functioning scores across time points in comparison to 
individuals whose symptoms had not remitted. There was also a significant main effect of 
age (B = 0.20, SE = 0.09, p = .024), wherein older age at the time of referral predicted 
significantly higher role functioning across time points.  Finally, there was a significant 
interaction between time and substance abuse, wherein the impact of substance abuse on role 
functioning changed between baseline and one year (B = 2.29, SE = 1.00, p = .022), and an 
interaction that approached statistical significance between six months and one year (B = 
1.87, SE = 0.96, p = .050) (see Figure 4). Whereas substance abuse was associated with 
higher role functioning at baseline and six months, by one year substance abuse predicted 
lower role functioning. In contrast, role functioning continued to improve over the course of 
the year for individuals who were not abusing substances.  
In the model predicting functional remission status, interaction terms for Substance 
Abuse X Time and Medication Adherence X Time were excluded due to the low frequency of 
functional remission across time points and insufficient population in some data cells. In the 
resulting model, the only significant predictor of functional remission status was age 
(adjusted OR = 1.21, 95% CI [1.09, 1.35], p < .001). Individuals who were older at age of 
 69 
referral were significantly more likely to be in functional remission across time points.  
Similar findings emerged for the outcome of working or attending school half time or more, 
wherein age emerged as the sole significant predictor (adjusted OR = 1.10, 95% CI [1.00, 
1.21], p = .042), with older age at referral predicting greater likelihood of being engaged in 
work or school half-time or more across time points. There were no significant main effects 
or interactions in the model predicting RAS scores.  
Sensitivity analyses. 
Because some participants were missing data at one or both of the post-baseline 
visits, sensitivity analyses were conducted to examine whether differential attrition could 
have biased the findings. Individuals were divided on the basis of their missing data pattern 
into the following dummy-coded groups; group 0 = reference group with one year visit 
present (n = 87), group 1 = discharged prior to one year for reasons other than refusing 
treatment or one year visit missing for unspecified reasons (n = 55), and group 2 = 
discharged prior to one year for refusing treatment (n = 21). For each of the functional 
outcomes of interest, this categorical group variable was entered into a GEE model adjusted 
for mean-centered age and sex along with Time X Group interaction terms. Because groups 1 
and 2 did not have one year data, only two levels of time (i.e. baseline and six months) were 
used in the interaction terms for each model.  Contrasts of slope estimates were selected to 
determine whether there were any significant differences in patterns of change on functional 
outcomes between baseline and six months based on group membership. 
There were no significant differences in patterns of change on RFS scores or on 
likelihood of working or attending school half-time or more between baseline and six months 
amongst the three groups. For the logistic GEE model predicting functional remission status, 
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there were only two individuals in group 2 (discharged for refusing treatment) with data at 
six months (both of whom were not in functional remission), and as a result only a contrast 
between change in groups 0 and 1 was examined. There were no significant differences in 
change in likelihood of being in functional remission between baseline and six months for 
those in groups 0 and 1.  
On the RAS, there was a significant difference in the pattern of change between 
groups 1 and 2, wherein individuals missing visits at one year for reasons other than refusing 
treatment endorsed increased subjective experiences of recovery between baseline and six 
months, whereas individuals missing one year visits for reasons of refusing treatment 
reported decreased experiences of recovery during that same time period (difference in slopes 
= 19.14, SE = 4.99, p <. 001) (see Figure 5). The difference in pattern of change between 
groups 0 and 2 also approached statistical significance, with the reference group 
demonstrating a more moderate (but still positive) change in recovery scores between 
baseline and six months, which was significantly different than the decrease in recovery 
scores for the refusal group (difference in slopes = 10.36, SE = 5.55, p = 0.062). Because 
time was treated as a categorical factor in each of the predictor analyses, it was not possible 
to average effects across missing data groups using a pattern-mixture model (Hedecker & 
Gibbons, 1997). 
One-way ANOVAs, Fisher exact tests and χ 2 analyses were used to test for 
significant differences in baseline demographic and clinical variables between the three 
missing data groups. There were no significant differences in baseline demographic variables 
including age, sex, race (African-American versus Caucasian), or insurance status (private 
versus not). Furthermore, the groups were not statistically different on any clinical outcome 
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measure at baseline with the exception of the BPRS activation factor (F(2, 118) = 3.88, p = 
.023). Tukey post-hoc comparisons of the three groups indicated that individuals missing 
data at one year for reasons of refusing treatment (i.e. group 2) (M = 6.92, 95% CI [5.07, 
8.78]) had significantly higher activation factor scores than those in the reference group (i.e. 
group 0) (M = 5.31, 95% CI [4.87, 5.75]), as well as significantly higher scores than those 
with one year visits missing for reasons other than refusing treatment (i.e. group 1) (M = 
5.30, 95% CI [4.71, 5.88]). Finally, there were no significant differences in symptom 
remission, substance abuse, or medication adherence status between groups at baseline. 
Overall, it appears that the results of GEE analyses predicting functional outcomes were not 
biased by missing data resulting from differential attrition patterns.   
 
 
 
 
 
 
  
 
  
DISCUSSION 
 The present study is the first systematic evaluation of a US-based multi-element 
treatment center for early psychosis. The aims of this naturalistic prospective study were 
threefold; to characterize the population presenting for treatment during the clinic‟s first three 
years of operation, to examine the course of the first year of treatment, and to explore 
correlates and determinants of short-term functional outcomes.  Discussion of the findings 
with respect to these three aims is presented below. 
Characteristics of an Early Psychosis Sample Presenting for Community-Based Care 
During the first three years of the clinic‟s operation, OASIS received over 400 
referrals from the surrounding community and was operating at full capacity within 
approximately 18 months of operation. Whereas OASIS received the majority of referrals 
during this initial period of operation from hospital clinics and other mental health providers, 
it is expectable that over time and with increased visibility in the community, referrals from 
non-psychiatric sources would increase, as has been seen in well-established early 
intervention programs such as EPPIC (McGorry et al., 1996). The individuals accepted for 
treatment for early psychosis at OASIS share characteristics with samples reported by other 
specialized early psychosis treatment programs with respect to sex, age, marital status, and 
ethnic composition (Addington et al., 2009; Malla et al., 2003). Although OASIS provides 
care for individuals with both affective and non-affective psychoses, an overwhelming 
majority (94%) of patients were diagnosed at baseline with non-affective psychoses. In 
addition, the findings attest to the fact that this is a high-risk population, as one fifth had been 
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arrested before entering treatment and approximately one quarter met criteria for either 
substance abuse or substance dependence. Overall, it is clear that there is a need for mental 
health services for this population in the state of NC and that a model of community-based 
multi-element treatment for early psychosis is feasible.  
OASIS is one of the few specialty clinics of its kind within a large geographic region 
in the United States. Although the cohort examined in this study cannot be considered 
epidemiological (inasmuch as there were other mental health care resources available to the 
target population), individuals receiving care at OASIS appeared to be similar to a large 
comparison sample from the rest of the state of North Carolina on most demographic and 
clinical variables (although formal inferential statistics were not conducted).  The possibly 
greater proportion of White/Caucasian individuals in the OASIS subsample may reflect 
differences in the ethnic composition of the county in which OASIS is situated, as compared 
to the state as a whole (Census Bureau, 2010). 
Additionally, baseline global functioning scores at OASIS were higher than those 
reported at other mental health treatment centers in NC, and they are also notably higher than 
those in published reports from other multi-element treatment programs (Conus et al., 2007; 
Meneghelli, Cocchi, & Preti, 2010). This difference likely reflects differences in treatment 
models and referral sources. Because OASIS does not offer its own inpatient services, 
patients are referred after their acute symptoms have resolved, in contrast to clinics such as 
EPPIC where the first point of contact after admission to the service may be an inpatient 
admission. For instance, Power et al. (1998) reported that 63% of patients were hospitalized 
within their first three months of treatment at EPPIC, and that the majority of these 
hospitalization occurred within the first day of contact. It is also important to note that the 
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population served at OASIS is best characterized as an “early psychosis” cohort 
representative of individuals within the broader critical period of early intervention, rather 
than a strictly “first-episode” or “first presentation to treatment” sample. 
Another unique characteristic of the sample is that a majority of individuals receiving 
care at OASIS had private insurance. This is in contrast to findings from a large, US-based 
epidemiological study of standard-care for first-episode psychosis, which included a larger 
proportion of uninsured individuals and fewer privately insured individuals  (Rabinowitz et 
al., 1998). However, it is difficult to draw any between-group comparisons based on 
insurance status, given the heterogeneity of financial and disability statuses within each of 
these groups. Furthermore, because OASIS is operated by a state-owned, not-for-profit 
healthcare system, uninsured individuals (as well as those whose insurance benefits have 
been exhausted) may be eligible to receive financial assistance from state funds. Because of 
this, the clinic is better able to provide services for the uninsured than are other community 
mental health models in NC who are limited to resources allocated by local management 
entities. Thus, it is not possible to make any confident conclusions about the association 
between service utilization and insurance status within our sample.  
In regard to service utilization, while the majority of individuals received individual 
therapy and medication management visits during the course of one year of treatment at 
OASIS, family therapy, multi-family therapy and community support were less frequently 
utilized services. However, there are several factors suggesting that the billing audit 
conducted for this study produced a conservative estimate of service utilization during the 
study period. First, there was a concurrent trial of an individual cognitive-behavioral therapy 
program (the Graduated Recovery Intervention Program; GRIP) (Penn et al., in preparation; 
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Waldheter et al., 2008) underway at OASIS during the study period, through which some 
individuals received up to 36 sessions of individual psychotherapy that were not captured in 
the billing audit.  Second, at various points during the study period, there were trainees 
offering services under the licenses of their supervisor, and in most cases these sessions were 
not billed.  And third, phone contact was also likely grossly under-captured, especially since 
crisis calls are not billed. As a result, the service utilization reported here may not adequately 
capture the treatment „dosage‟ received within a multi-element treatment center.  
It is not surprising that OASIS‟s service utilization statistics fell below those reported 
for the integrated arm of the OPUS trial, wherein at one year follow-up individuals had 
received a median number of 42 outpatient visits (as compared to 11 in standard care) 
(Petersen et al., 2005a). Whereas assertive community treatment is one of the chief 
components of the OPUS intervention program and others, such as LEO (Craig et al., 2004), 
care at OASIS is primarily clinic-based, with therapeutic services provided in the community 
(including in the clients‟ homes) based on individual need.  Indeed, one of the primary assets 
of the multi-element treatment model is that comprehensive services are offered under one 
roof. However, such clinic-based treatment comes with additional challenges to treatment 
engagement and participation.  
 Despite the fact that treatment engagement is a perpetual challenge in early 
intervention services, OASIS was able to successfully engage a high proportion of 
individuals entering treatment. Only 13% of the cohort was discharged for reasons of 
refusing treatment over the course of the first year. At EPPIC, the rate of disengagement over 
the course of 18-months, as defined by refusal of treatment or being untraceable despite 
clinician efforts, was 23% (Conus et al., 2010), and an early psychosis program in New 
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Zealand found 25% terminating despite therapeutic need (Turner, Smith-Hamel, & Mulder, 
2007).  In this study, an extremely conservative rate of disengagement (33%) can be 
calculated by including individuals who had geographic relocations, returned to work or 
school, left for reasons of program dissatisfaction, or missed two consecutive visits in the 
system, in addition to those who were discharged for reasons of refusing treatment.  
Nonetheless, these statistics reinforce the potential for multi-element early intervention 
services to engage young adults much more successfully than standard care (Garety & Rigg, 
2001) or in interventions limited to medication management alone (i.e. in drug trials for first-
episode psychosis) (Emsley et al., 2007; McEvoy et al., 2007), where rates of treatment 
disengagement of 40-50% have been reported over the course of one year. 
Likewise, treatment at OASIS was associated with high rates of adherence to 
antipsychotic medications. Seventy-six percent of individuals treated at OASIS were rated as 
adherent to their medication over the entire study period, and this rate is similar to 
medication adherence statistics recently reported in two Canadian centers for early psychosis 
(i.e. 76-83% adherent over the entire first year) (Addington et al., 2009). These rates are 
notably higher than those reported in standard care, particularly in comparison to findings in 
an epidemiological US sample that 60% of individuals receiving standard care became 
nonadherent to prescribed medication regiments within the year following an initial 
hospitalization for psychosis (Mojtabai et al., 2002). Adherence statistics from this study are 
also notably higher than those reported in drug trials for chronic schizophrenia (Lieberman et 
al., 2005a), as well as for early psychosis (McEvoy et al., 2007). These findings underscore 
the potential of multi-element programs to impact treatment adherence in early psychosis. 
One-Year Patient Outcomes 
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Over the first year of treatment, individuals in treatment at OASIS experienced 
significant improvements in global functioning and significant decreases in positive and 
negative symptom levels. These findings contribute to the growing body of evidence 
suggesting that multi-element programs facilitate symptom improvement during the early 
illness course (Harvey et al., 2007; Malla et al., 2005; Penn et al., 2005). Although the 
within-group effect sizes observed for symptom change in this study were small to moderate, 
the magnitude of change for positive symptoms was greater than that observed in the OPUS 
trial  (d = 0.19 on the SAPS), and equal to that observed for negative symptoms (d = 0.31 on 
the SANS), with each of these improvements being greater than those observed in standard 
care in the OPUS trial (Petersen et al., 2005a) (although formal statistical comparison of 
these effect sizes was not conducted). Large improvements in GAF scores, which tend to 
demonstrate larger correlations with symptom levels rather than functioning levels 
(Goldman, Skodol, & Lave, 1992; Hilsenroth et al., 2000; Moos, McCoy, & Moos, 2000; 
Moos, Nichol, & Moos, 2002; Skodol, Link, Shrout, & Horwath, 1988) support these 
conclusions.  
In this study, symptom remission was utilized as a benchmark of symptomatic 
improvement because it has shown promise of being a sensitive marker of more 
comprehensive clinical improvement across the illness course. There was a significant 
increase in the proportion of individuals meeting symptom remission criteria, as determined 
by severity only, from baseline to one year, with rates of remission at one year approaching 
those reported at other multi-element treatment centers using these same criteria (i.e. 69-
78%) (Addington et al., 2009; Cocchi et al., 2008; Menezes et al., 2009). Furthermore, 
OASIS had a favorable percentage of individuals who met remission severity criteria at one 
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or more study visits over the course of the year in comparison to the only other study that has 
reported on this same statistic in a multi-element treatment model for early psychosis (i.e. 
Addington & Addington, 2008b) (84% vs. 77%). 
To best understand these symptom improvements and the potential mechanisms of 
change within the multi-element treatment model, it is helpful to consider change that has 
been observed in medication trials. The percentage meeting severity remission criteria at any 
point during the first year of treatment at OASIS surpasses the rates of symptom remission 
reported in two large randomized, double-blinded trials of atypical antipsychotic medication 
effectiveness (84% vs. 58-70%), one of which used the same standardized remission criteria 
as our study (Emsley et al., 2007), and one of which used slightly modified remission criteria 
(McEvoy et al., 2007). Similarly, OASIS had a noticeably greater percentage of individuals 
experience symptom remission for a duration of at least six months (at some point during the 
course of one year) as compared to a randomized medication trial that monitored remission 
using the same criteria over a much longer study period of 2-4 years (i.e. Emsley et al., 2007) 
(63% vs. 24%). These descriptive comparisons suggest that treatment at OASIS may be 
associated with increased likelihood of meaningful symptom reduction above and beyond 
what is to be expected through medication management alone. 
One limitation of assessing symptom remission using BPRS scores is that, in 
comparison to the same remission definition as assessed using other measures such as the 
PANSS (Kay et al., 1987) or the SAPS and SANS (Andreasen, 1982; Andreasen & Olsen, 
1982), the BPRS does not include items that capture some central negative symptoms, such 
as avolition/apathy, anhedonia, or lack of spontaneity (Andreasen et al., 2005). Given that 
only one item pertaining to a negative symptom of schizophrenia is included in the definition 
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of symptom remission used in this study (i.e. Item 16, Blunted Affect), it is possible that 
some individuals who experienced symptom remission may still have demonstrated some 
negative symptoms that were not captured in this definition. 
Nonetheless, the negative symptom factor of the BPRS-E used in this study has 
demonstrated high correlations with specific measures of negative symptoms (Nicholson, 
Chapman, & Neufeld, 1995), which suggests that we may have been able to accurately assess 
changes in negative symptomatology independent of symptom remission. Of particular 
interest is the significant improvement in negative symptoms over the course of one year in 
the absence of significant decreases in depression. This replicates findings reported from an 
historically controlled study conducted at EPPIC, in which patients treated at EPPIC 
demonstrated sustained improvement in negative symptoms that were not observed for the 
historical control group, despite low and constant levels of depression for both groups 
(McGorry et al., 1996). The controlled EPPIC study did not control for doses or duration of 
antipsychotic medication treatment, and similarly for the purposes of the present study, we 
did not examine changes in medications across time periods.  Therefore, it is possible that 
changes in negative symptom levels may be impacted by changing antipsychotic medication 
profiles, as was observed in the OPUS trial (Petersen et al., 2005a). Nonetheless, these 
findings may point to an ability of specialized early intervention to impact negative 
symptoms, which have traditionally shown less improvement in standard care (Harvey et al., 
2007).  
The reduction in the rate of substance abuse over the course of the study also adds to 
the growing body of literature indicating that multi-element treatment for early psychosis is 
associated with rapid decline in substance abuse over the first several months of treatment 
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(Carr, Norman, & Manchanda, 2009; Hinton et al., 2007).  It is particularly notable that these 
reductions in substance abuse occur despite the absence of a specialized substance abuse 
intervention (Addington & Addington, 2001b; Archie et al., 2007; Hinton et al., 2007; 
Petersen et al., 2007). At OASIS, targeted substance abuse interventions (i.e. substance abuse 
assessment, individual and group sessions led by a certified substance abuse counselor 
following the integrated dual diagnosis modality of treatment) were developed after the first 
several years of clinic operation and therefore were not available to a large proportion of the 
study sample. During the initial years of clinic operation, substance abuse was addressed in 
psychoeducation provided in groups, individual therapy, and psychiatrist visits according to a 
phase-specific model of care for early psychosis. Although substance abuse reductions did 
not reach statistical significance in this study, these findings suggest that substance abuse is a 
potentially malleable treatment target in early intervention.    
A central finding of this study is that individuals receiving care at OASIS 
demonstrated significant improvements across functional outcome domains over the course 
of the first year of treatment. Individuals were significantly more likely to be involved in 
school at one year than at baseline, and there was a trend-level improvement in occupational 
status as demonstrated by an increased proportion of individuals working or attending school 
at least half-time at one year. In addition, the proportion of individuals neither in work nor 
school at one year (31%) is lower than reported at another multi-element treatment center 
(36% at EPP) (Addington, 2009), and in both the integrated and control arms of the OPUS 
trial (42% and 53%, respectively)(Petersen et al., 2005b). Improvement in objective 
functional outcomes are further demonstrated on a multi-dimensional measure of role 
functioning, wherein after one year of treatment at OASIS, individuals were significantly 
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more likely to have adequate to optimal role functioning across role functioning domains 
than they were at baseline, and these improvements demonstrated moderate to large effect 
sizes.  
It is notable that subjective experiences of recovery were among the few indices on 
which no significant improvement was observed. On the other self-reported measure in our 
battery, (i.e. the OQ), there was significant improvement in the symptom distress and social 
role domains, but not in the interpersonal relationship domain. This may point to the 
distinction between subjectively and objectively assessed functional outcomes, wherein an 
improvement in the size or availability of social networks (as evidenced in the significant 
improvements in the Immediate and Extended Social Networks items of the RFS) may not 
necessarily be associated with increased satisfaction with those networks or relationships 
(Priebe et al., 2000). It should be noted, however, that the average baseline score on the RAS 
was quite high (corresponding to a mean item score of 4.1 on a 5-point agreement scale). 
Therefore, one possible interpretation of the non-significant improvement on this measure is 
that many individuals may have been experiencing a positive sense of recovery at baseline 
which remained unchanged over the course of the study.  
The pattern of findings among one-year outcomes in this study may help further 
elucidate relationships between intra- and interpersonal facets of the broader recovery 
experience. The RAS has previously demonstrated significant positive associations with self-
esteem, empowerment and social support (Corrigan et al., 1999). Additionally, a  previous 
report examining baseline characteristics amongst a subset of individuals included in the 
present study found that greater perceived social support and lower levels of depression were 
significant predictors of  psychological well-being, a component of subjective quality of life 
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that taps positive aspects of mental health and wellness that are consistent with the recovery 
concept (Uzenoff et al., in press). Takings these preliminary findings into consideration, the 
lack of significant improvements in depression, experiences of recovery, and satisfaction 
with interpersonal relationships in this study highlights the complex relationships between 
subjective components of recovery from an initial psychotic episode. 
 Finally, care at OASIS was associated with a low hospitalization rate, as compared to 
other early psychosis treatment programs as well as to standard care. Twenty-seven percent 
of individuals treated at OASIS were hospitalized during their first year of treatment, which 
is similar to rates reported at two Canadian multi-element programs for FEP (i.e. 27-30%) 
(Addington et al., 2009), though rates from 5-59% have been reported elsewhere (Addington, 
2009; Petersen et al., 2005a).  This is also lower than a 12-month rehospitalization rate 
(36.5%) reported in an epidemiological study of standard care for individuals recently 
experiencing an initial hospitalization for psychotic disorders (Craig, Fennig, Tanenberg-
Karant, & Bromet, 2000). There was only one death due to suicide, and this rate of 0.6% is 
comparable with rates of suicide in the integrated care arm of the OPUS trial as well as the 
EPP program (Addington et al., 2004b).  
Predictors of Functional Outcomes 
This study proposed a novel definition of functional remission including adequate to 
optimal role functioning in the areas of occupational involvement, independent living skills, 
and involvement with social networks, as well as at-least half-time work or school 
involvement. By this definition, there was a significant increase in the proportion of 
individuals meeting functional remission criteria from baseline to one year, and like 
symptom remission, fewer were able to sustain this level of functioning for two consecutive 
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study visits. It is notable that in all cases, the sustained functional remission occurred 
between six months and one year, suggesting that enduring functional gains may take longer 
than symptomatic ones. Rates of functional remission were also much lower than rates of 
symptom remission, which has been widely observed in early psychosis using varying 
definitions of functional recovery (Cassidy et al., 2009; Crumlish et al., 2009; Emsley et al., 
2006; Menezes et al., 2009; Petersen et al., 2008; Whitehorn, Brown, Richard, Rui, & 
Kopala, 2002; Wunderink et al., 2009). 
 To better understand the relationship between clinical risk factors during the early 
course of treatment and comprehensive indices of recovery, we examined the impact of 
symptom remission, substance abuse, and medication adherence on several different 
functional outcomes. Symptom remission emerged as a significant predictor of role 
functioning across visits during the first year of treatment, which supports previous 
associations between symptom remission and clinician-rated functional outcomes (Boden et 
al., 2009; Helldin et al., 2007; van Os et al., 2006b). This finding contributes to the predictive 
validity of the symptom remission criteria set forth by the Remission in Schizophrenia 
Working Group within early psychosis populations, which has only been examined in two 
previous studies (Cassidy et al., 2009; Wunderink et al., 2009). The finding that symptom 
remission contributed significantly to changes in role functioning across domains provides 
support for the use of this measure as a clinically sensitive predictor of functional outcomes 
in first-episode psychosis, and contributes to a growing body of research indicating that 
symptom remission may be a necessary, but not sufficient, step towards functional recovery 
(Andreasen et al., 2005; Robinson et al., 2004; van Os et al., 2006a). 
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This study also adds to findings suggesting that substance abuse over the early course 
of treatment has a negative impact on functional outcomes (Lambert et al., 2005; Wade et al., 
2007). Whereas those abusing substances had higher role functioning at baseline and six 
months, by one year, these individuals were functioning at a lower level than those not 
abusing substances. In contrast, role functioning continued to improve for those who were 
not abusing substances over the course of the year. These findings point to the importance of 
developing interventions to detect and reduce persistent substance use during the early course 
of treatment, as has been done by Edwards and colleagues at EPPIC (Edwards et al., 2006; 
Edwards et al., 2003). These results are also consistent with evidence that, even for those 
abusing substances at the time of entry to treatment, substance discontinuation following an 
initial psychotic episode contributes to improved outcomes (González-Pinto et al., 2009).  
Surprisingly, neither symptom remission, substance abuse, nor medication adherence 
significantly predicted functional remission in our sample, nor did they predict one of its 
component criteria, working or attending school half-time or more. There are several 
potential explanations for these findings, including the likelihood that these binary measures 
were not sensitive enough to detect meaningful differences in a relatively small sample. In 
particular, the number of individuals achieving functional remission was quite low at each 
visit. It is also possible that the one year follow-up period was not long enough for most 
individuals to achieve the functional benchmarks examined in these analyses. For instance, 
Boden and colleagues (2009) found that at five years following initial presentation for an 
initial psychotic episode, symptom remission significantly predicted working or studying 
half-time or more, and symptom remission discriminated between those with „good outcome‟ 
in three different areas of functioning and those without. It is possible that both symptom 
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remission and substance abuse would show stronger associations to these objective measures 
of recovery in a longer-follow-up study.  
We also did not find any significant predictors of subjective recovery experiences in 
early psychosis. Previous studies have reported a significant impact of symptom remission on 
subjective outcomes, including satisfaction with life (Boden et al., 2009), well-being 
(Lambert et al., 2006) and self-reported quality of life (Emsley et al., 2007). There was a 
substantial amount of missing data from this measure, which may have limited our ability to 
detect relationships between recovery experiences and our predictor variables.  
Older age at the time of referral predicted significantly higher role functioning, 
working or attending school half-time or more, and being in functional remission. This robust 
effect likely points to a strong association between age of referral and age of illness onset, 
which has been observed in other early intervention studies (Malla et al., 2006) and is a 
primary marker of successful efforts at early identification. Indeed, age of illness onset is a 
well-known predictor of outcome in psychotic disorders, with younger age of illness onset 
showing significant associations to poorer long-term outcomes (DeLisi, 1992; Häfner, 
Löffler, Maurer, Hambrecht, & an der Heiden, 1999; Ho, Andreasen, Flaum, Nopoulos, & 
Miller, 2000). Unfortunately, we did not have a sensitive measure of duration of untreated 
illness, DUP, or premorbid adjustment, and therefore it is difficult to make definitive 
conclusions regarding this finding.   
Despite the missing data in this study, it appears that findings were not biased by 
differential patterns of attrition within the study cohort. However, sensitivity analyses 
revealed that individuals who left treatment against clinician recommendation experienced 
decreases in subjective sense of recovery early in the course of treatment. Given the fact that 
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this was the only significant difference to emerge between missing-data groups, these 
findings should be interpreted cautiously. However, this finding highlights the importance of 
fostering recovery-oriented attitudes and goals within individual and group therapies, as well 
as assessing subjective experiences of recovery as a means of reducing treatment 
disengagement during the critical period.  
Strengths and Limitations 
This study has multiple strengths. The prospective longitudinal study design allowed 
for careful examination of the characteristics of an early psychosis cohort presenting to a 
specialized, phase-specific treatment program, as well as the course of the first year of 
treatment. There have been few epidemiological studies of first-episode psychosis conducted 
in the US (e.g. Bromet et al., 1992; Tohen et al., 1992), and each of these has examined 
presentation and course in standard, rather than specialized care.  Indeed, this is the first 
examination of a multi-element treatment center for early psychosis in the US. The use of 
well-validated measures of symptoms, a consensus definition of symptom remission, and 
both subjective and objective measures permit comparisons of key outcomes across the early 
intervention literature based on standards of care set forth in the International Declaration on 
Early Psychosis (Addington, 2009; Addington et al., 2005; Addington et al., 2009; 
Addington et al., 2007b; Bertolote & McGorry, 2005). Findings highlight the possible 
efficacy of the OASIS treatment model across domains of recovery while expanding the 
growing literature regarding predictors and correlates of the early treatment course.    
Despite the benefits of the study‟s naturalistic prospective design, the lack of a 
control sample is one of the study‟s chief limitations. While we have made efforts to assess 
the representativeness of the OASIS sample within its immediate geographic surroundings 
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and to compare the clinical changes observed over the course of one year with those 
observed in other programs, without a direct control sample, we cannot confidently infer that 
outcome changes were due to the treatment offered at OASIS.  A second caveat pertains to 
the short follow-up period examined in the present study. Mid- to long-term follow-up 
studies of cohorts receiving specialized early intervention services have thus far returned 
mixed evidence regarding the durability of treatment gains (Addington & Addington, 2008a; 
Bertelsen et al., 2008; Mihalopoulos et al., 2009). Longer follow-up periods are needed to 
better understand the more prolonged recovery trajectory. A central point of investigation for 
longer-term follow-up studies is determining rates of treatment “completion,” though this 
remains a complex determination that will vary from program to program based on treatment 
model. At OASIS, treatment is offered for five years (including maintenance medication 
management visits on a biannual basis), however other services have limited services to two 
(Malla et al., 2003; McGorry et al., 1996; Petersen et al., 2005b) to three years (Addington & 
Addington, 2001a) with varying protocols for maintenance medication management and 
follow-up.  
Because study evaluations were conducted as part of routine care, full-time clinicians 
were charged with completing all rater-based study assessments. One consequence of this 
approach to data collection is that raters were not trained to reliability for the purpose of this 
study. Furthermore, because data was collected before or during sessions otherwise dedicated 
to case management, therapy, and medication management, the demands of clinical care may 
naturally have taken precedence over data collection and/or entry, thereby contributing to 
some of the missing data in this study. Given that the majority of missing data forms were 
self-report measures, it is also possible that there was some resistance on the part of patients 
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to filling out forms during visits.  One solution to ensuring that data are more routinely 
collected in this type of setting is to increase the extent to which the data is incorporated 
directly into care and fed back to clients at each point in the service provision chain. 
Consistent outcome evaluation may represent an ongoing administrative challenge for 
programs with fewer resources.  
Other limitations of this study include the lack of an adequate measure of DUP. 
Although information regarding the onset of symptoms was routinely collected during clinic 
intake assessments, calculations of DUP were discontinued within the first year of the 
clinic‟s operation due to concerns regarding the validity of client- and family-report during 
unstructured intake assessments. Other measurement issues include an inability to confirm 
whether or not symptom remission was sustained for a period of at least six months, given 
that assessments were only conducted at six month intervals. As mentioned previously, a 
strength of this study was a newly proposed definition of functional recovery, however this 
binary measure may not have been sensitive enough to detect meaningful differences.  
Conclusions 
Over the past 20 years, the multi-element treatment model has developed to fill a 
need for timely, comprehensive, phase-specific care in early psychosis. This study provides 
preliminary evidence for the efficacy of a US-based multi-element treatment center in 
addressing the clinical needs of an early psychosis population and improving short-term 
outcomes. Furthermore, this study provides novel insights regarding the impact of substance 
abuse and symptom remission on functional outcomes in early psychosis, and highlights the 
need for efforts to improve treatment engagement and retention in this population. 
Remaining challenges include tailoring interventions to address depression and experiences 
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of well-being, hope, self-efficacy and empowerment, given findings that dimensions of 
recovery may not improve concurrently with traditional symptom indices. Additionally, 
because rates of achieving functional benchmarks remain quite low within the first year of 
treatment, the potential benefits of vocational training should continue to be evaluated in this 
population (e.g. Killackey et al., 2008). Continued evaluation of a multi-element treatment 
model is a necessary component of ongoing efforts to identify best practice in intervention 
for early psychosis, and in providing widespread access to optimal, evidence-based care. 
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Table 1.  
Schedule of study assessments. 
 
Intake Baseline 6 months
 
1 Year Discharge
 
Demographics
 
X  X X X 
Health Insurance status X  X X X 
School/Vocational status X  X X X 
DSM-IV diagnosis  X X X X 
BPRS  X X X X 
GAF  X X X X 
AUS/DUS
 
 X X X X 
OQ  X X X X 
RFS
 
 X X X X 
RAS
 
 X X X X 
Hospitalizations  X X X X 
 
Note. All assessments collected at the 6 month visit are collected at each 6 month interval 
thereafter (i.e. 12 months, 18 months, etc.) for the duration of the patient‟s engagement with 
the clinic. Multiple discharges are possible if care is reinstated at OASIS after an initial 
discharge. Demographic information, health insurance status, and school/vocational status 
are first obtained at intake to the clinic, and then subsequently reviewed and updated at each 
subsequent visit. BPRS = Brief Psychiatric Rating Scale; GAF = Global Assessment of 
Functioning; AUS/DUS = Alcohol Use Scale/Drug Use Scale; OQ = Outcome 
Questionnaire; RFS = Role Functioning Scale; RAS = Recovery Assessment Scale. 
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Table 2.  
Demographics for OASIS Study Cohort 
 Male Female Total 
    
Subjects, n 110 53 163 
Age, M (SD) 22.7 (4.2) 24.0 (5.1) 23.1 (4.5) 
Race, n     
     White/Caucasian 81 26 107 
     African American/Black 23 21 44 
     Asian 5 3 8 
     Hispanic/Latino 0 3 3 
     Native American 1 0 1 
Marital status, n     
     Never been married 104 45 149 
     Married 4 4 8 
     Divorced 2 2 4 
     Separated 0 2 2 
Living situation, n    
     Private residence 100 49 149 
     Group home 9 2 11 
     Transitional housing 0 2 2 
     Support apartments 1 0 1 
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Table 3. 
Baseline Characteristics of OASIS Subsample vs. NC-TOPPS Early Psychosis Sample  
 
OASIS (N = 22) NC-TOPPS (N = 1439) 
  
 
Ethnicity (%) 
   African-American  
   White-Caucasian 
   Other 
41% 
55% 
5% 
60%  
33%  
7%  
Sex (% male) 68% 69%  
Living Situation (% private residence) 77% 75%  
Marital Status (% never married) 91% 87%  
Employment (% in labor force) 55% 51%  
Under Correctional Supervision (%) 9% 9% 
History of Arrest (%) 23% 32% 
Substance Abuse Diagnosis (%) 14% 18%  
Substance Dependence Diagnosis (%) 23% 14%  
Global Functioning
a
 M (SD), Mdn, range 51.09 (12.17), 50, 35-80 42.64 (8.52), 41, 15-85 
  
 
 
Note.
 
There were differences in the methods of ethnic categorization between the two datasets: within 
the OASIS database, “Hispanic/Latino/Spanish” was considered to be a distinct ethnic category, and 
within the NC-TOPPS database, “Hispanic/Latino/Spanish origin” was recorded independently from 
„Race/Ethnicity.‟ Therefore, for the OASIS sample, the 5% of clients identified as 
Hispanic/Latino/Spanish are included in the „Other‟ category in this table. Within the NC-TOPPS 
sample, the 4% of clients identified as being of Hispanic/Latino/Spanish origin may be represented 
within any of the racial/ethnic designations included in this table. Percentages for substance abuse and 
substance dependence included for the OASIS sample include those in either active or partial 
remission. Remission status was not specified within the NC-TOPPS data available for this study.  
 Global functioning was measured using the Global Assessment of Functioning (GAF); NC-TOPPS 
data available for N = 1419. 
  
9
3
 
Table 4. 
  
Service Utilization (Number of Contacts) By Intervention Type and Insurance Status 
 
 Type of Insurance 
 Self-Pay 
(n = 35) 
Medicaid/Medicare 
(n = 28) 
Private 
(n = 96) 
Medicaid/care + Private 
(n = 3) 
All insurance types 
(N = 163) 
 M (SD) Mdn M (SD) Mdn M (SD) Mdn M (SD) Mdn M (SD) Mdn 
                
Medication 
Management 
8.77 (10.81) 5.00 10.64 (11.86) 6.50 7.29 (7.14) 6.00 26.67 (19.50) 27.00 8.54 (9.50) 6.00 
Individual 
Therapy 
7.97 (12.45) 1.00 2.43 (5.37) 0 5.55 (8.80) 1.00 7.67 (13.28) 0 5.54 (9.39) 1.00 
Group 
Therapy 
1.20 (3.71) 0 0.29 (0.71) 0 1.78 (4.38) 0 2.33 (4.04) 0 1.40 (3.84) 0 
Family 
Therapy 
1.43 (3.60) 0 1.64 (1.89) 1.00 1.45 (2.13) 1.00 5.33 (7.51) 1.00 1.54 (2.64) 1.00 
Multi-Family 
Therapy 
1.23 (3.80) 0 1.32 (3.87) 0 1.35 (2.81) 0 5.67 (8.96) 1.00 1.39 (3.39) 0 
Initial 
Assessment 
1.29 (0.79) 1.00 0.96 (0.88) 1.00 1.45 (0.77) 2.00 2.00 (0.00) 2.00 1.34 (0.80) 2.00 
Phone Contact 0.31 (1.21) 0 0.00 (.00) 0 0.36 (1.56) 0 0.00 (0.00) 0 0.28 (1.32) 0 
Community 
Support 
0.11 (0.68) 0 1.14 (3.93) 0 0.01 (0.10) 0 2.67 (4.62) 0 0.28 (1.80) 0 
Total # of 
contacts 
22.31 (25.89) 11.00 18.43 (15.96) 12.00 19.25 (16.82) 13.00 52.33 (56.13) 31.00 20.31 (20.24) 13.00 
 94 
Table 5. 
 
Correlations between Service Utilization and One-Year Outcomes 
 
 
Type of Service 
 
 
Medication 
Management 
Individual 
Therapy 
Group 
Therapy 
Family 
Therapy 
Multi-family 
Therapy 
Community 
Support 
Total 
Hours 
        
Outcome Measure       
BPRS (Total) .21 .13 -.06 .19 -.05 .12 .19 
   Positive .17 .03 -.03 -.04 0 .12 .12 
   Activation .14 .03 -.12 .21 -.09 0 .10 
   Negative -.03 .02 .04 .03 .03 -.05 .01 
   Depression/ 
   Anxiety 
.16 .23* -.13 .10 -.11 0 .15 
GAF
 
-.28* 0 -.04 -.17 -.12 -.25* -.23* 
OQ (Total) .14 -.16 .36* -.15 -.15 .09 .03 
   Symptom  
   Distress 
.18 -.13 .38* -.16 -.12 .12 .09 
   Interpersonal    
   Relationships 
.14 -.08 .28 -.08 -.14 -.01 .05 
   Social Role -.04 -.30* .29* -.21 -.21 .07 -.17 
RFS (Total) -.31* -.05 -.09 -.20 -.10 -.36** -.29* 
   Working 
   Productivity 
-.42* -.09 -.12 -.20 -.17 -.40** 
-
.38** 
   Independent  
   Living 
-.22 .09 0 -.19 0 -.39** -.15 
   Immediate   
   Social Network 
-.13 -.04 -.05 -.13 -.04 -.23 -.15 
   Extended Social  
   Network 
-.27* -.14 -.16 -.18 -.11 -.23 -.31* 
RAS
 
.04 .07 -.19 .11 .05 -.24 .04 
        
 
Note. Significant correlations are bolded, * p < .05, ** p < .01. 
BPRS = Brief Psychiatric Rating Scale; GAF = Global Assessment of Functioning; AUS/DUS = 
Alcohol Use Scale/Drug Use Scale; OQ = Outcome Questionnaire; RFS = Role Functioning Scale; 
RAS = Recovery Assessment Scale.
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Table 6.  
 
Symptom and Functional Outcomes at Baseline and Over Course of One Year 
 
 Total Sample  Paired Sample 
        Baseline                    Baseline                  1Year 
 N M (SD)  n M (SD) M (SD) t p d 
             
BPRS (Total) 121 39.57 (10.86)  66 38.77 (10.65) 33.12 (8.50) 3.82 <.001** 0.47 
  Positive  7.35 (4.00)   6.92 (3.60) 5.64 (2.94) 2.50 .015* 0.31 
  Activation   5.48 (2.03)   5.35 (1.88) 4.64 (1.08) 2.95 .004** 0.36 
  Negative   5.11 (2.56)   5.41 (2.72) 4.52 (2.21) 2.55 .013* 0.31 
  Dep/Anx  7.36 (3.33)   7.08 (3.24) 6.32 (2.64) 1.71 .092 0.21 
GAF 162 50.51 (11.42)  84 49.98 (10.62) 65.52 (15.23) -9.56 <.001** -1.04 
OQ (Total) 94 64.20 (26.27)  28 57.43 (25.05) 45.61 (26.38) 2.94 .007** 0.56 
  Symptom  
  Distress 
 
37.02 (16.33) 
  
33.71 (16.14) 25.46 (15.93) 2.99 .006** 0.56 
  Interpers.       
  Relation. 
 
14.72 (6.98) 
  
12.36 (5.95) 11.75 (7.06) 0.71 .481 0.13 
  Social Role  12.46 (5.48)   11.36 (5.57) 8.39 (4.96) 3.17 .004** 0.60 
RFS (Total) 121 17.14 (5.28)  55 16.75 (5.19) 20.36 (5.25) -6.08 <.001** -0.82 
  Working  
  Productivity 
 
3.48 (1.92) 
  
3.29 (1.94) 4.62 (1.99) -5.83 <.001** -0.79 
  Independent  
  Living 
 
4.44 (1.58) 
  
4.42 (1.65) 5.24 (1.50) -3.82 <.001** -0.52 
  Immediate   
  Soc. Netwk   
 
4.74 (1.37) 
  
4.78 (1.26) 5.53 (1.12) -4.77 <.001** -0.64 
  Extended  
  Soc. Netwk 
 
4.48 (1.36) 
  
4.25 (1.31) 4.98 (1.35) -4.30 <.001** -0.58 
RAS (Total) 102 166.01 (21.52)  29 167.62 19.48 175.00 25.03 -1.54 0.134 -0.29 
             
 
BPRS = Brief Psychiatric Rating Scale; GAF = Global Assessment of Functioning; AUS/DUS = 
Alcohol Use Scale/Drug Use Scale; OQ = Outcome Questionnaire; RFS = Role Functioning Scale; 
RAS = Recovery Assessment Scale.  * p < .05, ** p < .01.
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Table 7. 
Occupational Status for Subsample with Paired Data at Baseline and One Year (N = 86) 
 
Baseline 
 
One Year 
 
School Involvement 
   
School Involvement 
 
Employment Status 
None  < Half-time  ≥ Half-time Total (%) 
 
None < Half-time  ≥ Half-time Total (%) 
   
 
 
     
Unemployed  48.8% 10.5% 4.7% 64%  31.4% 20.9% 5.8% 58.1% 
Working < Half-time  7.0% 4.7% 0% 11.6%  4.7% 7.0% 0% 11.6% 
Working ≥ Half-time 23.3% 1.2% 0% 24.4%  27.9% 2.3% 0% 30.2% 
   
 
 
     
Total (%)  79.1% 16.3% 4.7% 100% 
 
64% 30.2% 5.8% 100% 
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Table 8. 
 Symptom and Functional Remission Status for Subsample with Paired Data at Baseline and One-Year  
 Baseline One Year  
 
n (%) n (%) 
   
All available paired data 
  
   Symptom Remission (severity criterion only) (N = 66) 27 (41%)  45 (68%)  
   Functional Remission (N = 55) 2 (4%)  7 (13%)  
   
Only cases with both symptom and functional remission data (N = 43) 
  
   Symptom Remission (severity criterion only)  15 (35%) 27 (63%) 
   Functional Remission 1 (2%)  4 (9%) 
   Of those in symptom remission, % in functional remission 1 (7%)  3 (11%)  
   Of those in functional remission, % in symptom remission 1 (100%) 3 (75%) 
   % meeting both symptom and functional remission criteria 1 (2%) 3 (7%) 
   
 
Note. All data in this table consider symptom remission as defined only by the severity (i.e. mild or less) criterion. 
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Table 9. 
 
Correlations among GEE predictors and covariates 
 
      
 
Substance 
Abuse  
Medication 
Nonadherence  
Symptom 
Remission  
Sex Age 
      
      
Substance Abuse __ .12 -.11 -.20** -.09 
Medication Nonadherence  __ -.06 .11 -.09 
Symptom Remission   __ -.01 .07 
Sex    __ .14** 
Age     __ 
      
 
** p < .01
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Figure 1. OASIS treatment flow for the period June 1, 2005—June 1, 2009. 
 
 
 
 
Note. 
a
Data available for N = 116; 
b
Data available for N = 87. 
Accepted for treatment 
N = 255 
Screen fail n = 150 
Psychosocial intake visit 
N = 224 
6-Month visit 
N = 132a 
Baseline visit 
N = 200 
Consults n = 4 
At-risk n = 33 
Study cohort (psychosis) 
N = 163 
Discharged n = 31 
Discharged n = 33 
Phone screening 
N = 405 
 
No-shows n = 31 
No-shows n = 14 Consults n = 10 
1-Year visit 
N = 101b 
Recontact n = 2 
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Figure 2. Cumulative OASIS enrollment during the first 18 months of operation. 
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Figure 3. Primary diagnoses at baseline. 
 
 
Note. Data available for n = 161 
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Figure 4. Interaction of substance abuse status by time in GEE model predicting RFS scores. 
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Figure 5. Interaction of missing data group by time in GEE model predicting RAS scores. 
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APPENDIX 
Measures 
Brief Psychiatric Rating Scale – Extended Versions (BPRS-E) (Lukoff, Liberman, & 
Nuechterlein, 1986) 
 
Total scale (α = .80) 
 
Item 1. Somatic concern 
Item 2. Anxiety 
Item 3. Depression 
Item 4. Suicidality 
Item 5. Guilt 
Item 6. Hostility 
Item 7. Elated Mood 
Item 8. Grandiosity 
Item 9. Suspiciousness 
Item 10. Hallucinations 
Item 11. Unusual thought content 
Item 12. Bizarre behavior 
Item 13. Self-neglect 
Item 14. Disorientation 
Item 15. Conceptual disorganization 
Item 16. Blunted affect 
Item 17. Emotional withdrawal 
Item 18. Motor retardation 
Item 19. Tension 
Item 20. Uncooperativeness 
Item 21. Excitement 
Item 22. Distractibility 
Item 23. Motor hyperactivity 
Item 24. Mannerisms and posturing 
 
Items by Four-Factor Solution (Velligan et al., 2005) 
 
Positive symptoms (α = .74) 
 
Item 10. Hallucinations 
Item 11. Unusual thought content 
Item 12. Bizarre behavior 
Item 15. Conceptual disorganization 
 
Activation (α = .60) 
 
Item 19. Tension 
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Item 21. Excitement 
Item 23. Motor hyperactivity 
Item 24. Mannerisms/Posturing 
 
Negative Symptoms (α = .78) 
 
Item 16. Blunted affect 
Item 17. Emotional withdrawal 
Item 18. Motor retardation 
 
Depression/Anxiety (α = 0.76) 
Item 2. Anxiety 
Item 3. Depression 
Item 4. Suicidality 
Item 5. Guilt 
 
Outcome Questionnaire (OQ 45.2) (Lambert et al., 1996) – Items by subscale 
Note. * indicates items that are reverse-scored. 
Symptom Distress (α = .93) 
2.  I tire quickly 
3.  I feel no interest in things 
5.  I blame myself for things 
6.  I feel irritated 
8.  I have thoughts of ending my life 
9.  I feel weak 
10.  I feel fearful 
11.  After heavy drinking, I need a drink the next morning to get going (If you do not drink, 
mark "never") 
13.* I am a happy person 
15. I feel worthless 
22.  I have difficulty concentrating 
23.  I feel hopeless about the future 
24.*  I like myself 
25.  Disturbing thoughts come into my mind that I cannot get rid of 
27.  I have an upset stomach 
29.  My heart pounds too much 
31.* I am satisfied with my life 
33.  I feel that something bad is going to happen 
34.  I have sore muscles 
35.  I feel afraid of open spaces, driving, or being on buses, subways, and so forth 
36.  I feel nervous 
40.  I feel something is wrong with my mind 
41.  I have trouble falling asleep or staying asleep 
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42.  I feel blue 
45.  I have headaches 
 
Interpersonal Relations (α = .79) 
1.  I get along well with others 
7.  I feel unhappy in my marriage/significant relationship 
16.  I am concerned about family troubles 
17.  I have an unfulfilling sex life 
18.  I feel lonely 
19.  I have frequent arguments 
20.*  I feel loved and wanted 
26.  I feel annoyed by people who criticize my drinking (or drug use) (if not applicable, 
mark "never") 
30.  I have trouble getting along with friends and close acquaintances 
37.*  I feel my love relationships are full and complete 
43.*  I am satisfied with my relationship with others 
 
Social Role (α = .72) 
4. I feel stressed at work/school 
12.*  I find my work/school satisfying 
14. I work/study too much 
21.*  I enjoy my spare time 
28.  I am not working/studying as well as I used to 
32.  I have trouble at work/school because of my drinking or drug abuse (if not applicable, 
mark "never") 
38.  I feel that I am not doing well at work/school 
39.  I have too many disagreements at work/school 
44.  I feel angry enough at work/school to do something I might regret 
 
Total Score (α = .95) 
 
Recovery Assessment Scale (Giffort et al., 1995) 
 
Total score (α = .96) 
 
1. I have desire to succeed 
2. I have goals in life that I want to reach 
3. I believe I can meet my current personal goals 
4. I have a purpose in life. 
5. I like myself 
6. I have an idea of who I want to become 
7. I'm hopeful about my future 
8. I continue to have new interests 
9. It is important to have fun 
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10. Being able to work is important to me 
11. It is important to have healthy habits 
12. It is important to have a variety of friends 
13. Even when I don't care about myself, other people do 
14. I know when to ask for help  
15. I am willing to ask for help 
16. I ask for help, when I need it 
17. I have people I can count on 
18. If people really knew me, they would like me 
19. Even when I don't believe in myself, other people do 
20. I can handle what happens in  my life 
21. Things happen for a good reason 
22. Something good will eventually happen 
23. I am the person most responsible for my own improvement 
24. I can learn from my mistakes 
25. I can handle stress 
26. I have my own plan for how to stay or become well 
27. I understand how to control the symptoms of my mental illness 
28. I can handle it if I get sick again 
29. I can identify what triggers the symptoms of my mental illness 
30. I can help myself become better 
31. Fear doesn't stop me from living the way I want to 
32. I know that there are mental health services that do help me 
33. There are things that I can do that help me deal with unwanted symptoms 
34. I am a better person than before my experience with mental illness 
35. Although my symptoms may get worse, I know I can handle it 
36. If I keep trying, I will continue to get better 
37. Coping with my mental illness is no longer the main focus of my life 
38. My symptoms interfere less and less with my life 
39. My symptoms seem to be a problem for shorter periods of time each time they occur 
40. I can identify the early warning signs of becoming sick 
41. I know what helps me get better 
 
  
1
0
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Role Functioning Scale (Goodman et al., 1993) 
Total score (α = .86) 
 Score: Working Productivity 
Rate the client primarily in the most 
appropriate expected role (i.e. 
homemaker, student, wage earner). 
 
Independent Living, Self Care 
(Management of household, eating, 
sleeping, hygiene care) 
 
Immediate Social Network 
Relationships 
(Close friends, Spouse, Family) 
 
Extended Social Network 
Relationships 
(Neighborhood, community church, 
clubs, agencies, recreational 
activities). 
 
1 Productivity severely limited; often 
unable to work or adapt to school or 
homemaking; virtually no skills or 
attempts to be productive. 
Lacking self-care skills approaching life 
endangering threat; often involves 
multiple and lengthy hospital services; 
not physically able to participate in 
running a household. 
 
Severely deviant behaviors within 
immediate social networks (i.e. often 
with imminent physical aggression or 
abuse to others or severely withdrawn 
form close friends, spouse, family; often 
rejected by immediate social network). 
 
Severely deviant behaviors within 
extended social networks (i.e. overtly 
disruptive, often leading to rejection by 
extended social networks). 
 
2 Occasional attempt at productivity 
unsuccessfully; productive only with 
constant supervision in sheltered work, 
home or special classes. 
Marked limitations in self-care/ 
independent living; often involving 
constant supervision in or out of 
protective environment (e.g. frequent 
utilization of crisis services). 
 
Marked limitations in immediate 
interpersonal relationships (e.g. 
excessive dependency or destructive 
communication or behaviors). 
 
Often totally isolated from extended 
social networks, refusing community 
involvement or belligerent to helpers, 
neighbors, etc. 
 
3 Limited productivity; often with 
restricted skills/abilities for 
homemaking, school, independent 
employment (e.g. requires highly 
structured routine). 
Limited self-care/independent living 
skills; often relying on mental/physical 
health care; limited participation in 
running household. 
 
Limited interpersonally; often no 
significant participation/ communication 
with immediate social network. 
 
Limited range of successful and 
appropriate interactions in extended 
social networks (i.e. often restricts 
community involvement to minimal 
survival level interactions). 
 
4 Marginal productivity (e.g. productive in 
sheltered work or minimally productive 
in independent work; fluctuates at home, 
school, in school; frequent job changes.) 
Marginally self sufficient; often uses 
REGULAR assistance to maintain self-
care/independent functioning; minimally 
participates in running household. 
 
Marginal functioning with immediate 
social network (i.e. relationships are 
often minimal and fluctuate in quality). 
 
Marginally effective interactions; often 
in a structured environment; may receive 
multiple public system support in accord 
with multiple needs. 
 
5 Moderately functional in independent 
employment, at home or school.  
(Consider very spotty work history or 
fluctuations in home, in school with 
extended periods of success). 
Moderately self-sufficient; i.e. living 
independently with ROUTINE 
assistance (e.g. home visits by nurses, 
other helping persons, in private or self-
help residences). 
 
Moderately affective continuing and 
close relationship with at least one other 
person. 
 
Moderately affective and independent in 
community interactions; may receive 
some public support in accord with need. 
 
6 Adequate functioning in independent 
employment, home or school; often not 
applying all available skills/abilities. 
Adequate independent living & self care 
with MINIMAL support (e.g. some 
transportation, shopping assistance with 
neighbors, friends, other helping 
persons). 
 
Adequate personal relationship with one 
or more immediate member of social 
network (e.g. friend or family). 
 
Adequately interacts in neighborhood or 
with at least one community or other 
organization or recreational activity. 
 
7 Optimally performs homemaking, 
school tasks or employment-related 
functions with ease and efficiency. 
Optimal care of health/hygiene; 
independently manages to meet personal 
needs and household tasks. 
 
Positive relationships with spouse or 
family and friends; assertively 
contributes to these relationships. 
 
Positively interacts in community; 
church or clubs, recreational activities, 
hobbies or personal interests, often with 
other participants. 
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